OnCo · weekly issue

OnCo weekly, 2026-10-01

810 changelog entries, 1 upcoming date, 12 corrections. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.

What changed this week

New pages, new data and fixes, from the changelog.

1 October 2026: Lymphoma: the biology of the germinal centre, and what a person actually decides
1 October 2026: The oldest three DLBCL rows retire, because the record now says the same thing three times
1 October 2026: Lymphoma molecular layer: the antigens and what they cost, the lesions, the classifications, resistance and the tests
1 October 2026: Lymphoma, the person: six decisions, six red cards, three first-sixty-days lists
1 October 2026: The weekly check now fails when a page grows past what a reader downloaded last week
1 October 2026: A ceiling on what a reader actually downloads, measured on the live site
1 October 2026: Lirafugratinib is approved, not phase 2, and the bot stops proposing one combination's approval for another
1 October 2026: chore: monthly identifier enrichment (HGNC, Wikidata) (#124)
1 October 2026: chore: refresh HTA decisions and survival snapshots (#123)
1 October 2026: chore: refresh pulse, abstract and citation snapshots (#122)
1 October 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
1 October 2026: chore: refresh institution research output from OpenAlex (#121)
1 October 2026: chore: draft change proposals that need review
30 September 2026: Four verified approval rows from the proposals queue, and two structure keys that stopped the build
30 September 2026: Page titles, second attempt: a noun phrase naming the thing and the dimension that orders it
30 September 2026: The unattended gates run the tests the way the ship chain does, so a weekly data refresh can merge itself again
30 September 2026: chore: refresh preprint tracker from Europe PMC
30 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE)
30 September 2026: chore: check regional approvals against the EMA register
30 September 2026: chore: weekly citation link check
30 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda)
30 September 2026: chore: draft change proposals that need review
29 September 2026: Lymphoma treatment rows, and red cards that no longer name a drug the reader is not taking
29 September 2026: Lymphoma treatment: 70 standard-of-care rows across 21 diseases, each citing its trial
29 September 2026: The software of oncology, and the top of a record page
29 September 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links)
28 September 2026: Every cancer-page section named for what is in it, in nine languages
28 September 2026: The block inside Symptoms and diagnosis is not called that too, and four pill labels follow the new names
28 September 2026: The page that shows what is waiting, with the queue read from the open pull requests
28 September 2026: A command for a person to type is not a change to the product
28 September 2026: The queue is a rendering of the open pull requests, refreshed on every ship
28 September 2026: The admin page waiting in its own queue
28 September 2026: The page that shows what is waiting, and says plainly what it is not
28 September 2026: The record page top waiting in the queue
28 September 2026: The top of a record page is the record again: a family strip of six, two paragraphs of summary, the clinic names readable, the model panel last
28 September 2026: The software map waiting in the queue
28 September 2026: The map a product proposal belongs in: 136 pieces of oncology software, each row saying whether anything outside the company backs it up
28 September 2026: The title review waiting in the queue
28 September 2026: Thirty page titles that named a format, could belong to any site, or needed a term first
28 September 2026: Product changes now wait for the owner, and the plan for the cancer page is written
28 September 2026: The approval mechanism belongs on main; the renames stay in the queue
28 September 2026: The cancer page measured before it is redesigned, and a plan the owner can approve part by part
28 September 2026: The first product change waiting in the queue
28 September 2026: Product changes wait for the owner; data ships
28 September 2026: Each section of a cancer page is now named for what is inside it, and the years index says which years it holds
28 September 2026: The front page links to 140 sections and shows almost none of them
28 September 2026: The prevalence matrix: 23 columns wide and growing with the corpus
28 September 2026: Visual first, and the measurement that would be misleading if taken naively
28 September 2026: Every page title, with the count of how many are one or two words
28 September 2026: The machine links, and the admission that seven patches are not a design
28 September 2026: The years index title, and the question of how it differs from the timeline
28 September 2026: The section names and the wall of links, with what each section holds and how many links a page carries
28 September 2026: The section called Evidence is called Trials and papers, which is what is in it
28 September 2026: Three more record-page asks on the roadmap, with what the print control actually does
28 September 2026: The fourth ask: the also-known-as line is the smallest type on the page
28 September 2026: Three owner asks on the roadmap: what a reader meets first on a record page
28 September 2026: Five weekly runs merged, the agent rules written down with the scripts they point at, and a card that can name no record no longer counts as one that lost one
28 September 2026: A card that can name no record is not a card that lost one
28 September 2026: Provenance regenerated with the private name redacted after the weekly run reintroduced it
28 September 2026: A locally installed skill directory is not part of this project
28 September 2026: The rules an agent needs, in the file every agent reads, with the scripts they point at now in the repository
28 September 2026: chore: render this week's issue to public/newsletter/
28 September 2026: chore: weekly fact check, audit, and provenance refresh
28 September 2026: chore: refresh public/votes.json from Discussions reactions
28 September 2026: chore: refresh trial counts from ClinicalTrials.gov
28 September 2026: chore: draft change proposals that need review
27 September 2026: A total review of fatalistic language: 153 phrases rewritten, the survival guard now says what a median is, and the red-flag card leads with calling
27 September 2026: A cancer with no NHS pathway page now says so in development as it does in production
27 September 2026: A word that is the source's is shown as the source's
27 September 2026: The half a keyword search cannot find: order, framing and the numbers printed as verdicts
27 September 2026: Say what the cancer does, not how to feel about it: fatalistic language out of OnCo's own voice, every quotation left exactly as its author wrote it
27 September 2026: Three dated fields the corpus lacked: accelerated approvals with their confirmations, a sourced first-description year on targets, and a trial start date
27 September 2026: Adenoid cystic carcinoma described without the word relentless
25 September 2026: Three dates the timeline was missing: every accelerated approval and what became of it, when each target was first described, and when each trial opened
25 September 2026: Measure what a reader downloads, not what the tests can render
25 September 2026: A record for every year and one timeline over all of them, with ten questions asked of the corpus and two it cannot answer
25 September 2026: Oncolytic virotherapy in full: four approved replicating viruses and not one randomised survival benefit, and the 2024 self-experiment read from its case report
25 September 2026: A record for every year in oncology, one timeline over all of them, and what the shape of the dates shows
25 September 2026: The for-me budget measures its own tiles, not the chrome every page carries
25 September 2026: Oncolytic virotherapy as a subject, not scattered records: the interferon defect, the approvals and what they really showed, and the virologist who treated herself
25 September 2026: Clicking a value in a table now filters by it: thirteen cells across eight tables, a year facet on trials, and a guard that a filter link can never come back empty
25 September 2026: Click the year to filter the table: thirteen cells across eight tables become filters
25 September 2026: Three owner asks on the roadmap: cells as filters, a record per year, and oncolytic virotherapy
25 September 2026: Six countries in depth, each read from its own registry and regulator: the United States, Germany, Japan, the United Kingdom, Israel and Russia
25 September 2026: Wave one of the country deep dives is done: six countries
25 September 2026: Four country pages said the figure excluded non-melanoma skin cancer; it never did
25 September 2026: The benchmarking partnership is hosted by Cancer Research UK, not founded by it
25 September 2026: Israel: a committee decides in public, once a year, inside a fixed sum, which cancer drugs the state will pay for
25 September 2026: One label over four health services: the United Kingdom deep dive, and the cost-per-QALY threshold the corpus had wrong
25 September 2026: Japan reads tenth in our own count and fifth in the world, so the Japan page is written from Japanese sources
25 September 2026: Russia read from Russian sources: the Herzen register and what it does not count, who pays, and the Eurasian approvals route
25 September 2026: Two country deep dives: the United States, where the question is who pays, and Germany, where a drug is paid for on the day it is approved and assessed afterwards
25 September 2026: The first two country deep dives: the United States and Germany
25 September 2026: In America the pill has a ceiling and the drip does not, and 239 accelerated approvals show what happens when nobody checks
25 September 2026: A red-card pattern can no longer match inside an unrelated word
25 September 2026: Compugen, which found PVRIG by predicting it, and the paper that first measured what a liposome does in a patient
25 September 2026: Germany pays for a new cancer drug on the day it goes on sale and asks what it is worth afterwards
25 September 2026: A blood-clot warning for a myeloma drug was reaching every fluoropyrimidine page, because the pattern matched inside the word pyrimidine
25 September 2026: Remove the scratch script used to survey what the corpus held for Israel
25 September 2026: Israel: the people and papers behind the country page, and the term for what a founder variant is
25 September 2026: The skin review: a page about a cream warned a reader about a blood clot, and an appraisal that refused a drug was recorded as one that funds it
25 September 2026: A second front page at /v2 for review, and table filters that find what you asked for: family cancers, phases in time order, search ranked by what you typed
25 September 2026: Country deep dives on the roadmap, ranked by what the corpus holds and by what that ranking gets wrong
25 September 2026: Filtering a table by a cancer family finds its subtypes, the phase filter runs in time order, and the facet search ranks what you typed
25 September 2026: The front page opens on the list again; the graph is one click away
25 September 2026: Four page-render tests were measuring how busy the machine is, not the code
25 September 2026: Four launch-list items were already done: tick them so nobody does them twice
25 September 2026: The answer to which page is mine now sits on the page a reader lands on, not the last tab
25 September 2026: Skin cancer on the NHS: nearly a third of England's urgent cancer referrals are for skin, and the commonest skin cancer is excluded from the standard that measures them
25 September 2026: Two layers of the skin round wrote the same trial: the ratchet caught it and the merge tool fixed it
25 September 2026: Record which of the skin layer's sources a program cannot open, checked one URL at a time
25 September 2026: The skin cancer NHS pathway, and the two exclusions that mean the published figures are not what they look like
25 September 2026: A reader on a breast subtype page now gets the cord compression card, and never two sepsis cards
25 September 2026: Skin cancer: what a person with a basal cell or squamous cell cancer faces, the family tree given its reason, and the counting rule that hides the commonest cancer there is
25 September 2026: The breast family review: the family page duplicates nothing, but the two receptor pages it routes to said everything twice
25 September 2026: What a person with a basal cell or squamous cell skin cancer actually faces, and a rule that lets a row cite the leaflet that carries its sentence
25 September 2026: The treatment of the keratinocyte cancers: the margin, Mohs surgery, the creams and the light, radiotherapy, the hedgehog pathway and the transplant recipient
25 September 2026: Three review lessons from the skin layer: a citation that does not contain the claim passes every gate
25 September 2026: The rows about living with a skin cancer now cite the leaflet that actually contains the sentence, and the photodynamic therapy figures move to the cream the trials used
25 September 2026: The skin family given its routing, the keratinocyte cancers given their subtypes and staging, and the counting rule that governs every figure on them
25 September 2026: A patient leaflet may be the source for a row about living with a disease, if the row names who wrote it
25 September 2026: What a person with a basal cell or squamous cell skin cancer actually faces: the choice between surgery and its alternatives with the trial figures, the operation on the face, Mohs as a day, and the ones that are not cured
25 September 2026: The family roll-up does not assume who is reading, and stops printing the cancer's name twice in one sentence
25 September 2026: Family cancer pages now reach what their subtypes hold: 3,683 trials, 1,079 medicines and 3,534 centres that no family page could reach before
25 September 2026: A family page now shows the trials, medicines and centres its subtypes hold, grouped by the subtype each came from
25 September 2026: The breast family page given its surgery, its NHS pathway and its shared decisions, and 83 duplicate records retired onto the ones that carry the reading
25 September 2026: The prostate review found an appraisal that refused a drug recorded as merely restricting it, and the breast family page given the routing a reader needs
25 September 2026: Breast cancer in the NHS: the screening programme the site never had, the family history service, both referral routes, and four wrong or stale funding claims corrected
25 September 2026: One thing, one id: 83 duplicate records merged, with the rule, the helper and the ratchet the three reviews asked for
25 September 2026: Breast cancer, the shared treatment spine: 22 trials on the operation, the axilla, radiotherapy and reconstruction, read at twenty and twenty-five years
25 September 2026: Breast cancer, living with it: the surgery choice with the twenty-year figures, the axilla and lymphoedema, fertility, sensation, hair, and four red cards
25 September 2026: The breast family page: the routing a reader needs in one click, the shared story of grade, stage and the receptor tests, and the classification edition nobody had noticed changed
25 September 2026: Prostate review: the appraisal that refused abiraterone was recorded as one that restricted it, eleven papers written twice, and the screening trials the whole section rests on
25 September 2026: The lung review: 33 lines the layers had written twice folded away, four contradictory figures resolved against their sources, and two duplicate-key bugs the lung data exposed
25 September 2026: The lung review: a placeholder idea rewritten from the UK page's own gaps, 33 duplicated base lines folded, three papers that existed twice merged, and two duplicate-key bugs the lung data exposed
25 September 2026: Prostate cancer in depth: 57 trials from their publications, the receptor landscape from eighteen deposits, the March 2026 screening recommendation, and four wrong NHS funding rows corrected
25 September 2026: Wire the two prostate pathology terms into the papers that found them
25 September 2026: Prostate molecular: the androgen receptor's five escape routes, the repair genes the four PARP labels disagree about, and what a PSMA PET cannot tell you
25 September 2026: The explained page budget measures its furniture, not how much the corpus knows
25 September 2026: Prostate glossary: fifteen new terms, with the screening figures, the two endpoint definitions and PI-RADS against the NICE Likert scale
25 September 2026: Prostate cancer on the NHS: the screening committee's March 2026 recommendation from its own coversheet, the risk in Black men with its cohorts, and the 62-day standard prostate fails worst
25 September 2026: Prostate treatment from its trials: 57 randomised comparisons, what each option costs a man, and the four NICE refusals
25 September 2026: Prostate cancer: five orthogonal classifications settled, the Cambridge Prognostic Groups added, and the decisions written with the trial figures rather than the word side effects
25 September 2026: Register the twelve prostate glossary drafts and link them from the decisions that use them
25 September 2026: Prostate cancer evidence: the 44 papers that made the field, a roadmap in twelve eras, seven ideas and nine open problems
25 September 2026: Prostate cancer, living with it: the ProtecT trade-off in numbers, hormone therapy for the long run, and cord compression named as the emergency
25 September 2026: An agent that has only the origin can now find the corpus: MCP and llms descriptors under .well-known, licence and provenance on every API response
25 September 2026: Prostate cancer has five classifications at once, and only one of them makes pages
25 September 2026: How to read the UK bodies that answer a script with a wall
25 September 2026: Lung cancer on the NHS: the screening programme from its own protocol, 34 centres, 21 appraisals and 8 refusals, the deprivation gradient from four national sources
25 September 2026: The UK lung pathway hangs off the family, not one branch of it
25 September 2026: Lung cancer gets its UK and NHS layer: the screening programme with its risk thresholds, the deprivation gradient in four nations, 108 funding decisions and the reflex testing clock
25 September 2026: Lung cancer given its trials, its molecular landscape and its evidence: 36 trials written from source, three landscapes, 44 papers, a roadmap of eleven eras
25 September 2026: A standard-of-care row for the antibody-drug conjugates and bispecifics entering lung cancer
25 September 2026: Lung molecular layer: adenocarcinoma, squamous and small-cell landscapes read separately, PD-L1 by assay, why tumour mutational burden failed, and resistance mechanism by mechanism
25 September 2026: Approval dates cut back to what the FDA notification page shows
25 September 2026: Lung cancer evidence: 44 landmark papers from Doll and Hill to tarlatamab, a roadmap in eleven eras with a 2032 registry watch, and seven open questions
25 September 2026: Registry routing reads the title and conditions, not the eligibility text
25 September 2026: Roadmap page quoted the old review gauge label
25 September 2026: Write down the three gauges no script can move, and what the owner holds
25 September 2026: Lung registry snapshot gets a breadth rule, later lines get their trials, and Ask keeps its floor
25 September 2026: Lung cancer given a family and a patient side: five tiers under lung-cancer, ten decision rows, 86 appointment questions, six red-card sets
25 September 2026: Europe PMC snapshots for 1,545 records, 42 logos, and a collection that had borrowed a charity's mark
25 September 2026: Take the backlink fill back out: it costs 0.002 of Ask recall, and the floor does not move
25 September 2026: Lung cancer: the patient side, written so a person who smoked and a person who never smoked are both addressed
25 September 2026: Read the three new lung pages in the dev server and drop one redundant alias
25 September 2026: Three more lung glossary terms the other layers will need, and an outlook paragraph on the family page
25 September 2026: Glossary terms: four Wikipedia links found, 58 absences recorded as checked
25 September 2026: Lung taxonomy settled and the core layer written: the family now hangs together, and lung cancer is described from its sources
25 September 2026: Lung cancer treatment layer: 884 registry trials, 31 landmark trials and the England access rows
25 September 2026: A test that fails when a gauge's denominator moves and its label does not
25 September 2026: Backlink fill for 1,002 weak records: two acronym collisions fixed first
25 September 2026: Provenance was blind to the generated files: 1,486 records get their commit line back
25 September 2026: Three gauges were measuring the wrong population; fix the questions, not the targets
25 September 2026: Colorectal reviewed against its sources: duplicate treatment rows folded, eleven NICE errors corrected, RAS wild-type recorded as a biomarker, 1,406 links checked
25 September 2026: Review the colorectal deep spike: fold the duplicated rows, settle the contradictory figures, fix eleven NICE errors and add the RAS wild-type readout
25 September 2026: Colorectal cancer deep spike complete (core, 710 trials, molecular landscape, evidence and roadmap); red cards re-sourced against the live toolkit; pages no longer grow with what is known about a reference; weekly jobs merge only when the gates pass
25 September 2026: Roadmaps and dossiers made robust to corpus growth: a reference costs the same whatever is known about it, the dossier export is a file, and no bot merges a tree the tests have not seen
25 September 2026: Check every cited URL and fix the one that was dead
25 September 2026: Register the colorectal treatment spike, its helper files and the sponsor supplement with the audit
25 September 2026: De-duplicate the NICE NG151 link across the three colorectal patches, and the CMS paper on its own term
25 September 2026: Thirteen glossary terms the evidence, living-with and molecular layers asked for, and the eight living-with drafts registered
25 September 2026: Colorectal: the historical trials the evidence and molecular layers cite, and targets for ten pipeline drugs
25 September 2026: Colorectal cancer deep spike, round one: the UK and NHS pathway across four nations with the national audit indicators, decisions, first 60 days, red cards and the adjuvant chemotherapy aid
25 September 2026: Red flags re-sourced: the UKONS triage tool found at its new URL, nine thresholds quote-checked against it, six redirects fixed, soft 404s caught by the weekly link check
25 September 2026: Colorectal: company links for the trials the registry names, and the sponsor backfill that keeps the rankings honest
25 September 2026: Colorectal molecular layer: 38-row genomic landscape from eight cBioPortal cohorts, sidedness as biology, the adenoma and serrated routes, CMS, immunity and ctDNA, with 47 paper records
25 September 2026: Colorectal cancer, the UK and NHS layer: the screening programme and its four-nation differences, the faecal immunochemical test that now governs referral, the National Bowel Cancer Audit, 13 NICE appraisals with the 2026 bevacizumab reversal, and the UK trial legacy
25 September 2026: Colorectal cancer deep spike: the evidence, the roadmap and the ideas
25 September 2026: Colorectal core, second pass: sidedness and consensus molecular subtype supplements, the screening standards source, and three claims tightened against their sources
25 September 2026: Colorectal: anti-EGFR rechallenge and the microsatellite-stable immunotherapy attempt
25 September 2026: Colorectal trials: cross-links into the records already in the corpus, and two corrections
25 September 2026: Colorectal cancer, living with it, care and decisions: ten decision rows, 74 appointment questions, a 19-item first 60 days checklist, six red-card sets and a NICE NG151 adjuvant decision aid
25 September 2026: Fold the duplicates the base colorectal record and spike carried: five history entries, seven biomarker lines, three state-of-the-art points and three open problems written twice
25 September 2026: Colorectal treatment layer: 38 hand-written trials from MOSAIC to ALTAIR, 661 registry trials, verified NICE and FDA approval rows, palliation
25 September 2026: Colorectal core layer: sourced epidemiology, the early-onset rise, risk, referral, screening, staging, pathology and prevention on the colorectal record; four subtype pages and eleven glossary terms
24 September 2026: LAUNCH: pancreatic spike and the cooperative-group home ticked
24 September 2026: Pancreatic reviewed against its sources: duplicates folded, figures settled, 1,006 links checked, mobile overflow fixed
24 September 2026: Pancreatic deep spike review: duplicates merged across seven files, daraxonrasib approval and NICE terminations settled, 13 paper duplicates supplemented, 47 redirected URLs rewritten, seven glossary terms and two journals, UK and tool pages lay out at 390 px; docs/PANCREATIC-QA.md
24 September 2026: Pancreatic cancer deep spike, round four: the molecular landscape with allele-level KRAS shares, subtype classes, precursor sequence and 82 papers
24 September 2026: Pancreatic molecular layer: the genomic landscape, subtypes, precursors, stroma and monitoring markers with their cohorts
24 September 2026: Pancreatic cancer deep spike, round three: 30 trials with outcomes, 284 registry trials, verified NICE and label rows, fifteen standard-of-care rows; Ask ranking weights curated records
24 September 2026: Ask concept index: inverse document frequency over curated records only; extractive recall 0.408 to 0.427, floor raised to 0.42
24 September 2026: Pancreatic treatment layer gates: cooperative groups under companies, pancrelipase flagged supportive, deep-dive tag described, stroma-enzyme schematic rule
24 September 2026: Pancreatic cancer deep spike, round two: the record extended with sourced epidemiology, risk, diagnosis and surveillance, six subtypes, 22 terms, 34 papers and a twelve-era roadmap
24 September 2026: Pancreatic core: classical versus basal-like (GATA6) and clinical benefit response terms for the evidence layer, high-risk individual folded into familial pancreatic cancer, disease-free survival note on the EFS term; the other requested ids resolve to existing records
24 September 2026: Pancreatic treatment layer: ESPAC-1 record, shorter TL;DRs, duplicate label links removed, explained-page budget note
24 September 2026: Pancreatic evidence: UNICANCER is a cooperative-group company, listed under companies
24 September 2026: Pancreatic treatment layer: 32 hand-written trials, 284 registry trials, drug approvals by regulator, standard-of-care export
24 September 2026: Pancreatic core: register the seven living-with glossary drafts (enzyme draft folded into pancreatic-enzyme-replacement, new-onset diabetes alias repointed), drop URLs the UK and living patches already link, subtype rows cite the neoadjuvant term rather than PRODIGE 24 so /explained/ stays under budget, audit list and stale zh summary updated
24 September 2026: Pancreatic cancer evidence: 34 Europe PMC paper records, a roadmap from Whipple 1935 to the 2031 registry watch, nine ideas
24 September 2026: Pancreatic cancer deep spike, round one: the UK and NHS pathway with the national audit findings, decisions, first 60 days, red cards and the first-treatment aid
24 September 2026: Pancreatic core layer: sourced epidemiology, risk factors, presentation and emergency share, diagnosis, resectability and TNM 8, pathology and precursors, surveillance programmes and outlook on the pancreatic record; six WHO subtype pages; thirteen glossary terms; five supplements
24 September 2026: Pancreatic cancer living with it, care and decisions: ten decision rows, 90 hand-written questions, first 60 days checklist, six red-card sets with the 111 and 999 wording, first-treatment decision aid from NICE NG85, sourced living-with notes on 26 side-effect and procedure records
24 September 2026: Pancreatic cancer UK and NHS page: NG12 diabetes rule, 28/31/62-day standards, NPaCA 2026 findings, 23 HPB hubs, NICE TA476/TA440/TA750/TA1052 and SMC decisions verified, PERT audit gap, EUROPAC and Precision-Panc legacy, four-nation registry figures
24 September 2026: Cooperative groups have one home: 35 trial groups move from institutions to cooperative-group companies with redirects
24 September 2026: One home for cooperative groups: 35 consortium institutions become cooperative-group companies (row 251)
24 September 2026: TNBC reviewed against its sources: figures reconciled, duplicates folded, 822 links checked
24 September 2026: Roadmap watch row: text column shrinks and wraps on phones
24 September 2026: TNBC QA: de-duplicate the six patches, correct KEYNOTE-522, BRCA share, NG101 1.3.6, TA992 and TROPION-Breast05, fix four dead links, roadmap and UK page fit 390 px; docs/TNBC-QA.md
24 September 2026: Wave 4: 99 cancer entity pages under the taxonomy rule; roadmaps page their eras; subtype pages rank below their parents in Ask
24 September 2026: Ask OnCo retrieval: subtype capped below its parent, provenance weight shared by both stages; extractive recall 0.403 to 0.411, floor held at 0.41
24 September 2026: LAUNCH: decisions and shipping of 25 Sept 2026
24 September 2026: Section planner test allows eight paged sections for NSCLC after the lung histologies; wave 4 pages weigh 0.7 in the Ask index
24 September 2026: Wave 4 cancer pages, family 7: sixteen pituitary, thymoma, salivary, cervical, vulvar and vaginal entities; roadmap Progress row
24 September 2026: Cancer hubs with section sub-pages, TNBC deep spike complete (core, treatments and 235 trials, molecular landscape), Ask recall repaired, route progress bar and edge caching, Methods and models glossary with 129 terms
24 September 2026: Roadmap pages: eras collapse behind Show era pills fed by /api/v1/roadmaps/<id>.json; watch table paged past 20; 300 KB markup budget
24 September 2026: Ask OnCo retrieval: drop function words and rank by kind and name in the word search; extractive recall 0.329 to 0.416, floor 0.41 with a ratchet
24 September 2026: Wave 4 cancer pages, family 6: fourteen rare tumour entities; cancer map SVG budget 320 KB
24 September 2026: TNBC treatment: reword a code comment to the page name
24 September 2026: TNBC treatment: LOTUS, PAKT, SCAN-B and ZEST detail, registry trials linked to subtype pages, test fixtures for the new rows
24 September 2026: Wave 4 cancer pages, family 5: sixteen lymphoma and leukaemia entities from WHO-HAEM5
24 September 2026: EntityDetail: remove the conflict markers committed with the architecture merge, drop the unused Tip import
24 September 2026: TNBC molecular layer: sourced genomic landscape, Lehmann and Burstein subtypes, ancestry and founder mutations, ctDNA studies, assay-specific PD-L1 and HER2-low thresholds, 55 landscape papers
24 September 2026: Wave 4 cancer pages, family 4: twenty colon, kidney and testicular entities; sibling linker so no new page arrives orphaned
24 September 2026: TNBC core: register the eight living-with glossary terms drafted by the living file, drop the brand-name aliases that hijacked Ask, trim two TL;DRs and a jargon phrase
24 September 2026: TNBC treatment deep dive: trial and drug records, approvals by regulator with NICE appraisal numbers, 229 registry trials, standard-of-care rows
24 September 2026: record-fold test: TNBC ceiling follows the new layers until the hub architecture lands, then drops to 300 KB
24 September 2026: CanSim terms, methods group: 58 "Methods and models" glossary terms with one-line definitions and why they appear in cancer papers; gap document gets a Done column
24 September 2026: CanSim terms, oncology group: 70 sourced glossary terms and the cancer-ai-vocabulary hub, 11 HGNC-sourced gene targets, TCGA cohort codes as cancer aliases, 12 data-source rows, Methods and models category
24 September 2026: Loading experience: navigation progress bar, route skeletons, intent prefetch on dense lists, pages hot at the edge, above-the-fold checks
24 September 2026: Decisions page holds 390 px: referenced-record and guideline pills truncate with tooltips, grid children may shrink
24 September 2026: TNBC core layer: sourced epidemiology, risk, presentation, diagnosis, pathology, staging, screening and outlook on the tnbc record; twelve subtype pages; nineteen glossary terms
24 September 2026: Modality hubs for twelve formats, TNBC deep spike round one (UK and NHS pathway, evidence and roadmap, decisions, first 60 days, red cards, after-chemotherapy aid), supportive care flag on 55 drugs, 22 cooperative-group records
24 September 2026: Geography section fits 390 px: grid items may shrink and source labels wrap
24 September 2026: Wave 4 cancer pages, family 3: fourteen breast histologies under breast-cancer from the WHO 2019 breast classification
24 September 2026: TNBC living with it, care and decisions: eleven decision rows, 77 hand-written questions, first 60 days checklist, three red-card sets with the 111 and 999 wording, after-chemotherapy decision aid, sourced living-with notes on 20 side-effect and procedure records
24 September 2026: TNBC UK and NHS layer: pathway page for tnbc with the screening caveat, NG12 and NG101 steps, every NICE and SMC decision including the TA992 refusal against SMC2608, R208 and M234 tests, eight UK-open trials with sites, TNT, POSH/OlympiA and PARTNER legacy, registry figures read from PHS, WCISU and NICR downloads, Breast Cancer Now and three researcher records, named gaps
24 September 2026: WIP: tnbc-core spike draft before merging main
24 September 2026: Cooperative groups as company records: cooperative-group company type with browser facet, glyph pill and tooltip; 22 group records (GORTEC, German CLL Study Group, French Sarcoma Group, AGO, AIO, MRC CTU, HORG, DPCG, DBCG, DAHANCA, GERCOR, ISG, SSG, EMN, IFM, ALFA, AMC, OCOG, KGOG, SARC, FIL, FILO) linked to 41 corpus trials as sponsor; sponsor aliases carry their ids and the IFM and KGOG mis-resolutions are fixed; the trials fetchers link and never give products to them
24 September 2026: Supportive care medicines: supportive drug flag on 55 records, "Supportive care" pill with glyph and tooltip, Purpose facet on /drugs/, excluded from the home treatments count, the product rankings and the treatment references on standard-of-care rows; EMA and FDA fetchers flag candidates by a stated indication rule
24 September 2026: Cancer records as a hub with ten sections: registry, section pages, shared strip, sections.json, budgets and deep-link tests
24 September 2026: Wave 4 cancer pages, family 2: ten lung histologies under nsclc from the WHO 2021 thoracic classification
24 September 2026: Front navigation: the kinds drawn as a linked graph, the body map as the entry point on phones; ship chain builds on Vercel only
24 September 2026: TNBC evidence: 45 papers verbatim from Europe PMC (guidelines, receptor and basal-like discovery, BRCA1 founder mutations, disparities, subtypes, pCR and RCB, platinum, CREATE-X, OlympiA updates, PD-L1 assays, TILs, TROPION-Breast02, CAPItello-290, HER2-low, ctDNA), tnbc-roadmap with 14 eras and a registry watch list to 2033, nine ideas
24 September 2026: Modality lens: /modalities/ and twelve format hubs assembling what the corpus records per shape of medicine
24 September 2026: Home page: the counts grid becomes a living graph of the kinds, with the body map as the entry point on phones
24 September 2026: Wave 4 cancer pages, family 1: entity pages under the seven parents without subtype records, taxonomy rule in docs/CANCER-PAGES.md
24 September 2026: LAUNCH: the ship chain no longer builds locally; Vercel builds and the chain verifies the alias
24 September 2026: LAUNCH: issue and PR sweep of 24 Sept, checkpoints, target statuses, ivermectin
24 September 2026: Ivermectin: the trial evidence so far, with the label toxicity table and the papers under expressions of concern stated
24 September 2026: Ivermectin evidence page: drug record with label toxicity table, four registry trials, 22 papers with expressions of concern and retraction stated, compact fenbendazole and mebendazole records, per-file citation test
24 September 2026: Checkpoint families mapped with immune and cell-cycle hubs, 26 new targets; 31 reader proposals applied as 23 trial records and 27 papers; Cancersim terms gap filed
24 September 2026: Cancersim terms gap: 378 of 504 terms not yet in OnCo, listed by bucket with the decision the methods terms need; IMPROVEMENTS row 250
24 September 2026: Target specificity and distribution on 904 targets with where each is found, gallbladder decision aids and comparison, world map of gallbladder cancer rates, six EU register rows decided by hand, PALD1 rewritten
24 September 2026: Issue 98: LITESPARK-011 (NCT04586231) readout written onto the record: Lancet 2026 dual primary progression-free and overall survival rows and toxicity as stated in the abstract, ASCO GU 2026 response, duration and treatment-related toxicity rows marked as conference data, Motzer 2026 paper record linked, plain-English summary, simple sentence and Chinese TL;DR
24 September 2026: Issue 97: INSITE (NCT03686215) trial record for pegulicianine with the NEJM Evidence 2023 coprimary endpoints and the existing Smith paper linked, pegulicianine.trials wired; status mixed because the sensitivity threshold was not met
24 September 2026: Issue 96: HBI0101 / NXC-201 multiple myeloma phase 1 (NCT04720313) trial record with the Haematologica 2023 response, survival and cytokine release endpoints, Asherie 2023 paper record, nxc-201-car-t wired to the trial and to multiple myeloma
24 September 2026: Issue 95: ScreenTrustCAD (NCT04778670) trial record for Lunit INSIGHT MMG with the Lancet Digital Health 2023 paired-reader detection endpoints, Dembrower 2023 paper record, lunit-insight-mmg.trials wired
24 September 2026: Issue 94: PSMA-PreRP (NCT03368547) trial record for Illuccix and 68Ga-PSMA-11 with the JAMA Oncology 2021 nodal accuracy endpoints, Hope 2021 paper record, illuccix.trials and ga68-psma-11.trials wired
24 September 2026: Issue 80: Vistogard Studies 1 and 2 (NCT01432301) trial record and Cancer 2017 paper; uridine-triacetate.trials wired with label link
24 September 2026: Issue 79: Study 0201 (NCT00003991) trial record and Blood 2006 paper; histamine-dihydrochloride.trials wired
24 September 2026: Issue 78: Study 201 (NCT00168064) trial record and JAMA Dermatology 2013 paper; mechlorethamine wired to the trial and to cutaneous-t-cell-lymphoma
24 September 2026: Issue 77: Study 2005-01 (NCT00358501) trial record and Blood 2016 paper; defibrotide.trials wired with label link
24 September 2026: Issue 76: CT041-ST-01 (NCT04581473) enriched in place with Lancet 2025 outcome and paper; satricabtagene-autoleucel.trials wired, false rivoceranib link and stale skip dropped
24 September 2026: Issue 75: MSB-GVHD001 (NCT02336230) trial record and BBMT 2020 paper; remestemcel-l.trials wired
24 September 2026: Issue 93: ROMAN (NCT03689712) trial record for avasopasem manganese with the eClinicalMedicine 2025 severe oral mucositis endpoints, Anderson 2025 paper record, avasopasem-manganese.trials wired; status mixed because the paper records the FDA complete response
24 September 2026: Issue 72: FOCUS (NCT02678572) enriched in place with Ann Surg Oncol 2024 outcomes; hepzato.trials wired with paper and label links
24 September 2026: Issue 71: eXalt3 (NCT02767804) enriched in place with JAMA Oncology 2021 outcomes; ensartinib cites the paper and label; stale zh TL;DR dropped
24 September 2026: Issue 70: Act.In.Sarc (NCT02379845) trial record and Lancet Oncology 2019 paper; nbtxr3.trials wired
24 September 2026: Issue 69: ROCKstar (NCT03640481) trial record and Blood 2021 paper; belumosudil.trials wired
24 September 2026: Issue 92: VISION (NCT02864992) enriched in place for tepotinib with the Paik NEJM 2020 response, duration and toxicity outcomes and the existing paper linked; capmatinib-tepotinib.trials wired to GEOMETRY mono-1 and VISION; geometry-mono-1 leads capmatinib.trials; simple sentence and Chinese TL;DR follow the record
24 September 2026: Issue 68: ARCHER 1050 (NCT01774721) enriched in place with separate Wu 2017 and Mok 2018 rows and papers; dacomitinib cites both
24 September 2026: Issue 67: ASCEND-4 (NCT01828099) enriched in place with Lancet 2017 outcomes and paper; ceritinib cites the paper
24 September 2026: Issue 66: CK-301-101 (NCT03212404) trial record and JITC 2023 paper; cosibelimab.trials wired, label and paper links replace the generic FDA listing
24 September 2026: Issue 65: ALTA (NCT02094573) trial record and JCO 2017 paper; brigatinib.trials wired to ALTA and ALTA-1L
24 September 2026: Glossary and record pages: checkpoint disambiguation term owns the bare word, Checkpoint families pills on target, term, pathway, technology and mechanics stage pages
24 September 2026: Checkpoint hubs: /checkpoints/ with a pill switch, /checkpoints/immune/ with the interactive synapse, /checkpoints/cell-cycle/ with the cell-cycle ring, class tables, JSON companions, nav entry in nine languages
24 September 2026: Checkpoint map: typed taxonomy of immune and cell-intrinsic checkpoints, 26 new targets from HGNC and UniProt, derived rows and tests
24 September 2026: Issue 91: Alliance A071401 (NCT02523014) trial record for GSK2256098 with the JCO 2023 six-month progression-free survival endpoints, Brastianos 2023 paper record, gsk2256098.trials wired
24 September 2026: Issue 90: PREEMPT CRC (NCT04369053) trial record for SimpleScreen CRC with the JAMA 2025 accuracy endpoints, Shaukat 2025 paper record, simplescreen-crc.trials wired
24 September 2026: Issue 89: TRANSCEND (NCT05774756) trial record for setmelanotide with the NEJM 2026 body-mass index and hunger endpoints, Miller 2026 paper record, setmelanotide refreshed with the 19 March 2026 US approval for acquired hypothalamic obesity and a CORRECTIONS row
24 September 2026: Issue 88: UX023T-CL201 (NCT02304367) trial record for burosumab with the JBMR 2021 serum phosphorus and fracture-healing endpoints, Jan de Beur 2021 paper record, burosumab.trials wired
24 September 2026: Issue 87: PATRICIA (NCT00122681, HPV-008) trial record for the bivalent HPV vaccine with the Lancet 2009 vaccine-efficacy endpoints, Paavonen 2009 paper record, hpv-bivalent-vaccine.trials wired
24 September 2026: Issue 85: XM01-22 (ISRCTN08063129) trial record for epoetin theta with the Archives of Drug Information 2011 haemoglobin response and transfusion endpoints, Tjulandin 2011 paper record, epoetin-theta.trials wired
24 September 2026: Issue 84: rolapitant Study 3 (NCT01500226, TS-P04834) trial record with the Lancet Oncology 2015 delayed-phase complete response endpoint, Schwartzberg 2015 paper record, rolapitant.trials wired and label links made explicit
24 September 2026: Issue 64: PALD1 (paladin) rewritten from the primary papers instead of the proposed GeneCards text; hand-written target records from reader proposals live in src/data/targets-reader-edits.ts and replace the generated gene record of the same id
24 September 2026: PR 74 residue decided by hand: six EU rows from the EMA register pages (olaratumab revoked 2019, pixantrone expired 2024, alitretinoin withdrawn 2021, cediranib application withdrawn 2016, ensartinib and senaparib positive CHMP opinions as under review); pixantrone status corrected to withdrawn, IMP4927 identified as senaparib (Sepalna) with PARP target and aliases, cediranib aliases; 15 rows closed as non-cancer medicines or pending
24 September 2026: Issue 83: XM22-03 (EudraCT 2009-015999-10) trial record for lipegfilgrastim with the BMC Cancer 2013 cycle 1 neutropenia endpoint, Bondarenko 2013 paper record, lipegfilgrastim.trials wired, id allowlisted as a phase 3 without an NCT
24 September 2026: Issue 82: MNTX 302 (NCT00402038) trial record for methylnaltrexone with the NEJM 2008 coprimary laxation endpoints, Thomas 2008 paper record, methylnaltrexone.trials wired and label links made explicit
24 September 2026: Gallbladder cancer geography: GLOBOCAN 2022 rates by country and sex for 185 countries, a reusable CancerGeography choropleth with incidence, mortality and sex pills, the high-burden regions with their papers, Chile's GES prophylactic cholecystectomy programme, India's NCRP registry rates and Japan's registry and guideline practice, prevention evidence, India and Chile spotlights, a geography.json companion and a gallbladder section on /countries/in/
24 September 2026: Target specificity explainer links the Human Protein Atlas collection record, whose licence now reads CC BY-SA 3.0
24 September 2026: Target specificity tests: enums cover every populated value, every row has a note and an https source, the graph carries the fields, HER2 reads tumour-associated and many types with a tumour-agnostic mark, BCR::ABL1 tumour-specific and one type, CD19 lineage antigen, PD-1 immune; browser facet counts match the data; the explainer and the pills render
24 September 2026: Target specificity in the pages: pills with glyphs and tooltips on target pages, a "Where it is found" section from the Human Protein Atlas rows, specificity and cancer-type facets on the target browser and the gene hub, and the explainer at /targets/specificity/
24 September 2026: Target specificity: blood-cancer family regex no longer swallows "(all types)" names, family names for the merged blood families, own-record sources for targets the atlases do not cover
24 September 2026: IMPROVEMENTS: rows 150 to 249, the 100 upgrade ideas of 24 September 2026
24 September 2026: Target specificity and distribution: schema, fetcher and data for 904 targets with an approved or clinical-stage drug
24 September 2026: Record pages stay inside a phone screen at 390 px; 130 more trials carry posted registry results
24 September 2026: Gallbladder decision aids and comparison: polyp aid on the 2022 European guideline, incidental cancer aid on AHPBA, Søreide, Ethun and CAPBIL, gallbladder compared with cholangiocarcinoma and ampullary cancer
24 September 2026: Record pages fit a 390 px phone and lose the Tabs key warning: grid children shrink (min-w-0 on Neighbours and What changed cards, *:min-w-0 on EntityDetail grids), GuidelineChip and DrugChip wrappers cap at max-w-full, tables in EntityDetail, InvestorPanels, StartupPanels, BiomarkerDetail, PrevalenceTable, ToxicityTable, AccessTable and ResearchOutput scroll inside ScrollRow with the year bars; each tab's content is a fragment keyed on the tab id so Flight no longer hands Tabs a keyless array; one record of every kind is a width-only check in scripts/mobile-audit.ts
24 September 2026: Registry passes over the gallbladder spike: outcomes for every NCT trial without its own, status re-read for all 4,102 NCT trials, key papers for 10 gallbladder trials
24 September 2026: LAUNCH: gallbladder deep spike of 24 Sept 2026
24 September 2026: Gallbladder cancer deep spike, final round: review reconciled the six facets to their sources, Wales and Northern Ireland figures, Cancer Drugs Fund status, prescription and benefit rules, lighter cancer pages
24 September 2026: Gallbladder deep spike review: duplicate terms, trials and history entries become supplements, HER2 and NICE figures reconciled, dead and redirected links fixed, backlinks for the ctDNA roadmap and the chemo-immunotherapy pairing, long relation lists capped with deep links so the cancer page drops from 997 KB to 652 KB, QA checklist in docs/GALLBLADDER-QA.md
24 September 2026: Gallbladder UK layer, second pass: Wales and Northern Ireland registry figures with stage, Scotland checked and found not to publish C23, CDF list v1.365 status on every biliary drug, four-nation prescription and special-rules benefit pages, GLH turnaround statements, CAPBIL tied to BILCAP, Hassan Malik record
24 September 2026: Gallbladder cancer deep spike, round three: treatments and trials, 131 registry trials, approval rows with NICE numbers, standard-of-care rows
24 September 2026: Gallbladder evidence: ARTEMIDE-Biliary01 points at its existing registry record instead of a second trial record
24 September 2026: Gallbladder cancer deep spike: the record rewritten with UK and world figures, eight subtypes, molecular landscape, UK and NHS pathway page, 40 papers, roadmap and ideas, decisions, first 60 days and red cards; weekly bot refreshes merged
24 September 2026: Gallbladder cancer treatments and trials: surgery, adjuvant, systemic, HER2 and palliation records with 131 registry trials
24 September 2026: Gallbladder cancer deep spike, first round: the record rewritten with UK and world figures, eight subtypes, molecular landscape, decisions, first 60 days and red cards
24 September 2026: Citation counts for the gallbladder evidence papers
24 September 2026: Gallbladder cancer roadmap, ideas, guideline and trial papers, terms and history
24 September 2026: Gallbladder cancer evidence: surgical, staging, UK, polyp, prevention, HER2 and ctDNA papers from Europe PMC
24 September 2026: UK and NHS page per cancer: /cancers/<id>/uk/, cancer-page pill, sitemap and JSON companion
24 September 2026: Gallbladder cancer: UK and NHS layer data, HPB centres, AMMF and UK trialists
24 September 2026: Gallbladder cancer record rebuilt with sourced UK, world and US figures, TNM 8th edition in plain words, risk factors with evidence, screening rules and patient FAQ; eight subtype pages and ten glossary terms
24 September 2026: Spike patches reach every cancer record wherever it lives, and fail loudly when the cancer id is missing; gallbladder landscape guard test
24 September 2026: Spike patches also merge into NCI coverage cancer records
24 September 2026: Gallbladder cancer molecular layer: sourced genomic landscape, regional cohorts, premalignant sequence, immune findings, HER2 testing, 30 landscape papers; spike supplements onto records other files own
24 September 2026: Gallbladder cancer: cancer-scoped red cards, dated first-60-days checklist, incidental-cancer journey
24 September 2026: Pipeline engine: a biparatopic antibody with one declared target resolves both arms at high confidence; zovodotin is a named auristatin payload
24 September 2026: Gallbladder cancer living-with spike: decision rows, question set and glossary records
24 September 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
24 September 2026: chore: refresh pulse, abstract and citation snapshots (#86)
24 September 2026: chore: refresh institution research output from OpenAlex (#81)
24 September 2026: chore: EU regional rows read from the EMA register pages (#73)
23 September 2026: Top bar fits at 1280 px with a classic scrollbar
23 September 2026: LAUNCH: owner asks of 23 Sept 2026
23 September 2026: Drugs browser fits its card with capped cells and clearer approval years; NHS-Galleri performance paper, trial outcomes and Galleri test page
23 September 2026: Header fits a 1280 px window with a classic scrollbar: star count folds into its icon, tighter nav gaps and 13 px labels between xl and 2xl
23 September 2026: NHS-Galleri test-performance paper (Nature Medicine, 22 Sept 2026) as a paper record, trial rebuilt on the registry and the abstract, result on Galleri, MCED and the ctDNA roadmap
23 September 2026: Drugs browser fits at 1280 and 1440: capped list cells with a "+N more" pill, Approved as first year plus muted latest with region flags, results tables scroll inside their card only when measured too wide
23 September 2026: Biomarker readouts under their parent genes at /biomarkers/, genome hub pages its genes
23 September 2026: Gene hub pages its role sections: first 30 genes per role in the HTML, the rest from one tables file, role and evidence deep links over the full set
23 September 2026: Proposals bot merges register-verified rows itself, mechanics of cancer rebuilt with 56 stage pages, mobile patterns for views where a control drives a visual
23 September 2026: Regenerate target cross-references for the seven new parent targets (HGNC and ChEMBL, 23 Sept 2026)
23 September 2026: Dependency map gets a touch path, and wide matrices scroll inside their own box
23 September 2026: Biomarker pages: /biomarkers/ browser with gene, measurement, cancer and approval facets; readout pages with a Part of strip; target, drug, term and tumour-test pages link their readouts
23 September 2026: Biomarker readouts: 80 records under 40 parent genes, thresholds quoted from FDA labels and the companion diagnostic list
23 September 2026: Add the biomarker kind: schema, KIND_META, glyph, colours, nav and kind labels in nine languages
23 September 2026: Mechanics atlas: a page per stage and a light journey hub
23 September 2026: Cancer gene layer of 1,447 genes, open-source oncology map, evidence-backed combination proposals on the engine, daily spotlight, iodine target correction
23 September 2026: LAUNCH: proposals bot, what merges itself and what waits
23 September 2026: Nightly proposals: auto branch squash-merged after the gates, review PR labelled needs-review with a reason on every EMA row
23 September 2026: Proposals bot decides EU rows from the EMA medicine pages: page status, exact attribution, biosimilar rule, drift check, apply script
23 September 2026: Regional approvals io helper: parse and write the hand-written file with a round-trip test, and R() takes a source
23 September 2026: Two-column tools get a phone layout: sticky preview, Choose and View pills, inline results
23 September 2026: Cancer genes, tier 4: 389 genes associated with cancer without a proven role
23 September 2026: Cancer genes, tier 3: 332 drivers called by cohort mutation analysis
23 September 2026: Cancer genes, tier 2: 507 genes with clinical evidence on their variants
23 September 2026: Cancer genes, tier 1: 219 genes with an approved or late-stage drug recorded against them
23 September 2026: Cancer gene layer: target roles, evidence tiers and sources, fetch-cancer-genes script, genome hub and browser facets
23 September 2026: Home spotlight rotates by kind each day: one hero record per kind (most connected), build day's set in the HTML, reader's day swapped in from /api/v1/spotlight.json without layout shift
23 September 2026: ADC payload fields and setidegrasib note: record only what the records say
23 September 2026: Open pipeline engine, tag power search pages and full-width tabs, Edge type and For you filters, API licence wording, For me browser-only notice
23 September 2026: Open-source catalogue tests: unique ids, https URLs, SPDX or placeholder licences with notes, every corpus id exists, 200 sources on the generation date, curated entries generated or explained
23 September 2026: Open source in oncology page: paged browser with category, licence, language, openness and activity facets, intro on how oncology is done in the open, and cross-links from technology, collection, organisation and data-source pages
23 September 2026: Open-source oncology catalogue: schema, curated list of 379 projects and the fetcher that reads licence, stars and dates from the GitHub API
23 September 2026: Radioactive iodine no longer linked to SSTR2: I-131 enters thyroid cells through the sodium-iodide symporter, which has no target page yet
23 September 2026: Document the open pipeline: how proposals are scored, searched and contributed
23 September 2026: Sixty combination proposals, each searched against trials, papers and patents
23 September 2026: Schema for combination proposals: a scored, evidence-backed cell of the modular-drug grid
23 September 2026: api layout: drop the entries duplicated by the engine merge
23 September 2026: Record pages: full-width tab strip above both columns; tag chips open /tagged/ power-search pages
23 September 2026: API page licence wording matches the footer and about page; For me says it is browser-only with a signed-in version coming
23 September 2026: Open drug engine: every medicine taken apart into its modules, and the permutation grid per format with each cell classified from records
23 September 2026: Edge: filter by type or For you, with URL state, per-cancer deep links and per-type feeds
23 September 2026: Search ranks cancers and treatments first and groups results by kind
23 September 2026: Search ranks cancers and treatments above journals and papers, with kind-grouped dropdowns
23 September 2026: Top bar without the tagline, with the weekly bot refreshes merged
23 September 2026: Top bar without the tagline
23 September 2026: Top bar: drop the tagline beside the wordmark; it took space the navigation needs
23 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#61)
23 September 2026: chore: check regional approvals against the EMA register (#60)
23 September 2026: chore: refresh preprint tracker from Europe PMC (#59)
23 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#58)
23 September 2026: chore: weekly citation link check (#57)
22 September 2026: Health gauges explain people without papers by role and exempt the closed section list
22 September 2026: Kind-size gauge holds open kinds only: the 19 treatment fronts are a closed OnCo taxonomy and are named in the note
22 September 2026: People-papers gauge counts roles that produce no papers as explained: 1,528 of 1,547 with a note on who is still without
22 September 2026: LAUNCH: chains 101 to 104 ticked
22 September 2026: Kind browser pages ship 60 rows and load the rest on demand, 402 registry trials for drugs and technologies, glossary terms without a Wikipedia article say so
22 September 2026: Kind browsers page their rows: first 60 in the HTML, the rest from /api/v1/tables/kind-<route>.json
22 September 2026: Content roadmap: wave 5 trial run recorded, headline numbers refreshed from content:gaps
22 September 2026: Wave 5 technologies: 32 technologies without a trial gain 65 registry trials and 7 corpus links from ClinicalTrials.gov
22 September 2026: fetch-entity-trials: hold technologies whose aliases name something else, stop words for ex vivo, Catalyst, STRIDE and hormone names
22 September 2026: Wave 5 drugs: 142 drugs without a trial gain 337 registry trials and 19 corpus links from ClinicalTrials.gov
22 September 2026: 75 glossary terms marked wikipediaChecked 2026-09-22; NO_ARTICLE comment lists retired
22 September 2026: fetch-entity-trials: ClinicalTrials.gov trials for drugs and technologies without one (wave 5, second half)
22 September 2026: Terms record a checked-and-absent Wikipedia state: wikipediaChecked field, gauge counts it as explained, page says so
22 September 2026: fetch-term-wikipedia: Wikipedia links for glossary terms, exact title or redirect match with a sense check
22 September 2026: Paper pages for 736 cited DOIs, 1,381 bare references now link to them
22 September 2026: Wave 7 batch 4: the last 155 paper pages for cited DOIs, 736 in all, 1,161 citing records linked; Progress row
22 September 2026: fetch-cited-papers: a preprint is "posted on bioRxiv", not "published in bioRxiv (preprint)"
22 September 2026: Trial statuses follow the registry with dated notes, iobenguane records merged
22 September 2026: Wave 7 batch 3: 194 more paper pages for cited DOIs, 581 in all, 1,042 citing records linked; intismeran autogene gains its aliases
22 September 2026: Wave 7 batch 2: 192 more paper pages for cited DOIs, 387 in all, 905 citing records linked
22 September 2026: Wave 7 batch 1: 195 paper pages for the most-cited DOIs without one, 785 citing records linked
22 September 2026: fetch-cited-papers: name citing pages by kind and count only, no year in TL;DR or id
22 September 2026: Registry status data: 13 trial status changes from 3,542 ClinicalTrials.gov records (active -> completed 5, active -> recruiting 3, recruiting -> active 2, completed -> withdrawn 2, active -> withdrawn 1) with dated notes and why-stopped text; iobenguane-i-131 (Azedra) merged into i131-mibg with its approval, brand, aliases, links and a redirect stub
22 September 2026: Registry status pass: scripts/fetch-registry-status.ts reads overallStatus, whyStopped and the registry dates for every trial with an NCT id and writes src/data/trial-registry-status.ts, applied in src/data/index.ts through applyRegistryStatus with a dated note; result statuses kept, hand-written statuses newer than the registry never downgraded; iobenguane-i-131 listed as a duplicate of i131-mibg in dedupe MERGES
22 September 2026: Wave 7 fetcher for cited DOIs: scripts/fetch-cited-papers.ts writes a paper page per DOI a record cites without one
22 September 2026: Explained page pages its sections, four duplicate companies and one duplicate drug merged with redirects
22 September 2026: Page /explained/ sections at 10 rows: 1,135 KB to 561 KB of markup, budget lowered to 600 KB
22 September 2026: LAUNCH: content waves through chain 100
22 September 2026: Merge five duplicate records: Orca Biosystems into orca-bio, InxMed (Shanghai) into inxmed, Cellectis S.A. into cellectis, the second Valius Sciences into valius, and the gap-fill nogapendekin alfa inbakicept into nogapendekin-alfa; trials, cancers, drugs, investors, aliases, links and a logo move to the kept records, 30 references repointed, sponsor aliases updated, stale simple text and translations dropped, redirects and static stubs added; biocon/biocon-biologics, jw-pharmaceutical/jw-therapeutics, astrazeneca/fusion-pharma and gtx/oncternal-therapeutics reviewed and kept apart
22 September 2026: Duplicate-record finder and merger for companies: scripts/dedupe-companies.ts flags pairs by normalised name (legal suffixes, descriptors and city words stripped), shared website domain, or shared Wikidata or Wikipedia identifier, prints hand-reviewed MERGE and SKIP verdicts, and with --apply moves the loser's fields onto the winner, removes the loser literal, rewrites every reference across src/data (dropping duplicates inside id arrays, renaming or dropping keyed simple, translation and wikidata entries), moves or deletes the logo and registers the redirect build-redirect-stubs.ts expects; institutions and drugs are report-only unless listed as obviously identical; the source-editing helpers in scripts/orphan-links.ts are exported for reuse
22 September 2026: Papers for people and ideas, trials for ideas and drugs for companies from wave 6
22 September 2026: Content roadmap: wave 6 progress row (people without a paper 318 to 300, ideas without a key paper 1,104 to 1,026, ideas without a trial 1,047 to 1,044, companies without a drug 720 to 718) with what was held back and why
22 September 2026: Wave 6 company drugs: 2 companies gain a drug through the ClinicalTrials.gov lead-sponsor field (Impact Therapeutics IMP4927, R-Pharm RPH-051), each verified on the registry record; 75 other sponsors held back because their corpus trials name only comparators with a maker on record
22 September 2026: Registry results for 144 trials, 24 more standard-of-care trials with outcomes, papers and standard-of-care rows linked
22 September 2026: Wave 6 idea evidence: 78 ideas gain key papers (124 new Europe PMC records, 98 existing reused) and 3 gain trials (4 ClinicalTrials.gov phase 2 or 3 records written, 4 corpus trials linked), matched on the drug or target the idea's text names plus its cancer
22 September 2026: heavy-pages test: explained budget follows the corpus after the trial waves, with the paging rule for the next rise
22 September 2026: Content gaps: the trial-acronym measure treats the programme stem before a hyphen as a known trial name; roadmap notes the 33 remaining tokens are all in the wave SKIP list
22 September 2026: Content wave 3, rare cancers: FIRSTMAPPP, InPACT, GETUG 13, ADIUVO, ADIUVO-2, TROPHIMMUN and BALLAD, 4 with structured outcomes, 4 primary papers, 13 standard-of-care rows linked
22 September 2026: Content wave 3, myeloma: DRAMMATIC (SWOG S1803, MRD-guided maintenance after transplant) recorded from the registry and linked from the myeloma maintenance row; NCI sponsor-of-record institution links removed across the wave
22 September 2026: Content wave 3, endometrial: RAINBO programme (four molecular-class trials including POLEmut-BLUE de-escalation) recorded from the registry; POLE-ultramutated standard-of-care row linked
22 September 2026: Roadmap Progress: wave 7 registry outcomes row (144 of 2,845 ingested trials gain 272 outcome rows from 153 records with posted results; 114 requests)
22 September 2026: Wave 7 data: registry outcomes for the first 2845 registry-ingested trials by family burden (144 trials with 272 outcome rows from 153 records with posted results)
22 September 2026: Content wave 3, ovarian: AURELIA (bevacizumab with single-agent chemotherapy in platinum-resistant ovarian cancer) with structured outcomes and its JCO 2014 paper; two standard-of-care rows linked
22 September 2026: Wave 7 data: registry outcomes for the first 2500 registry-ingested trials by family burden (144 trials with 272 outcome rows from 153 records with posted results)
22 September 2026: Content wave 3, head and neck: CONTINUUM (sintilimab added to induction-concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma) with structured outcomes and its Lancet 2024 paper; standard-of-care row linked
22 September 2026: Wave 7 data: registry outcomes for the first 2000 registry-ingested trials by family burden (111 trials with 209 outcome rows from 117 records with posted results)
22 September 2026: Wave 6 people papers: 18 people gain up to three most cited papers each from Europe PMC by author and affiliation (46 new paper records, 6 existing reused), administrators filtered by role before searching, 2 ambiguous names skipped with reasons
22 September 2026: Content wave 3, colorectal: CAPP2 (aspirin in Lynch syndrome, 10-year follow-up) with structured outcomes and its Lancet 2020 paper; Lynch syndrome standard-of-care row linked
22 September 2026: Wave 7 data: registry outcomes for the first 1500 registry-ingested trials by family burden (85 trials with 171 outcome rows from 91 records with posted results)
22 September 2026: Wave 7 data: registry outcomes for the first 1000 registry-ingested trials by family burden (61 trials with 126 outcome rows from 65 records with posted results)
22 September 2026: Content wave 3, lung: IMpower010 is the existing registry record nct02486718, which gains the IMpower010 alias, its positive status and disease-free survival outcomes from the registry results section and the Lancet 2021 report; JCOG0802 skipped (UMIN only)
22 September 2026: Content wave 3, anal family: ANCHOR, POD1UM-303/InterAACT-2, InterAACT and NCI9673 with structured outcomes, 5 primary papers, 6 standard-of-care rows linked
22 September 2026: Explained page: the Open explanation pill carries only its label; glyph and Close state move to CSS; row classes and cross-reference titles shortened
22 September 2026: Content wave 3, sarcoma family: ACTG A5263/AMC 066 (paclitaxel against etoposide or bleomycin-vincristine with antiretroviral therapy for AIDS-associated Kaposi sarcoma) with structured outcomes and its Lancet 2020 paper; Progress table rows for gastric, pancreatic and sarcoma
22 September 2026: Content wave 3, pancreatic family: 7 standard-of-care trials (ESPAC-3, ESPAC-4, CONKO-001, NORPACT-1, LAP07, ESPAC-5, PRECEDE), 6 with structured outcomes, 6 primary papers, 7 standard-of-care rows linked
22 September 2026: LAUNCH: chains 97 and 98 ticked
22 September 2026: Wave 7 data: registry outcomes for the first 500 registry-ingested trials by family burden (39 trials with 78 outcome rows from 40 records with posted results)
22 September 2026: Wave 7 script: fetch-registry-outcomes.ts copies structured outcomes from the ClinicalTrials.gov results section into a side file merged by index.ts
22 September 2026: Content wave 3, gastric family: CLASSIC (adjuvant CAPOX after D2 gastrectomy) with structured outcomes and two primary papers; SKIP list extended for UMIN- and ISRCTN-only trials
22 September 2026: Wave 1 trial papers from Europe PMC, wave 3 standard-of-care trials, wave 5 targets and EMA products and sponsors, seven heavy table pages and idea rankings load rows on demand
22 September 2026: Paged tables: the heavy StaticTable pages carry 30 rows and fetch the rest from /api/v1/tables/
22 September 2026: Content wave 3: structured outcomes for 8 hand-written trials from the ClinicalTrials.gov results section (ARANOTE, CheckMate 915, PACIFIC-2, INTELLANCE-1, ATEMPT, ASPEN, DESTINY-Gastric02, AREN0532); roadmap Progress notes the families not reached
22 September 2026: Content wave 3, lymphoma family: 7 standard-of-care trials (FoRT, GALLIUM, RELEVANCE, TRIANGLE, SYMPATICO, BMT CTN 0803, PTLD-1), all with structured outcomes, 7 primary papers, 9 standard-of-care rows linked
22 September 2026: Content roadmap: wave 5 progress row (targets 30 to 0, EMA products 12 to 0, sponsor companies 21 to 15) with what was not written and why
22 September 2026: Wave 5 sponsor companies: 6 trial sponsors and 2 EMA authorisation holders from Wikidata and the ClinicalTrials.gov sponsor field (Criterium, Artios Pharma, Ambrx, Nerviano Medical Sciences, Qurient, Immunovaccine, Grünenthal, 4SC); drugs and companies waves registered
22 September 2026: Wave 5 EMA products: 7 register products written from their EPAR pages (crisantaspase, burosumab, epoetin theta, human normal immunoglobulin, fentanyl, resminostat, Tacquell), 3 matching faults fixed with aliases, vedolizumab excluded
22 September 2026: Wave 5 targets: 26 pages for the symbols two or more drug records name without a target page (NRAS, CD28, HLA-A, MPL, SHP2, STAT5, IKZF1, JAK1, CD80, ABL1, FAK, IKZF3, PTCH1, CD137, HIF-1α, IDO1, BRD4, IRF4, B7-H4, TET2, NF1, ACVR1, HOXA9, MEIS1, BIM, BAX)
22 September 2026: Content wave 3, childhood family: 9 standard-of-care trials (ANBL1221, ANBL0531, ANBL17P1, AEWS0031, SIOPEL-3, SIOPEL-4, AGCT1531, AHOD1331, EuroNet-PHL-C2), 7 with structured outcomes, 6 primary papers, 11 standard-of-care rows linked
22 September 2026: Content wave 3, brain and CNS family: 10 standard-of-care trials (ACNS1123, ACNS0122, ACNS0333, ACNS0121, NOA-08, SJMB12, ACNS1422, IELSG32, MATRix/IELSG43, INTUITT-NF2), 8 with structured outcomes, 8 primary papers, 12 standard-of-care rows linked
22 September 2026: Content wave 3, leukaemia family: 18 standard-of-care trials with registry records and structured outcomes, 12 primary papers, standard-of-care rows linked
22 September 2026: Fetched paper records link only their trial and journal; wave 1 progress row; citation counts for the new papers
22 September 2026: Idea rankings page carries the first 30 rows of each view and fetches the rest per view from /api/v1/ideas/rankings/<view>.json
22 September 2026: Prostate trials: key papers from Europe PMC for the prostate family
22 September 2026: Skin trials: key papers from Europe PMC for the skin family
22 September 2026: Colorectal trials: key papers from Europe PMC for the colorectal family
22 September 2026: Breast trials: key papers from Europe PMC for 77 trials, 85 new paper records, 22 long-term follow-ups
22 September 2026: Lung trials: key papers from Europe PMC for 125 trials, 134 new paper records, 25 long-term follow-ups
22 September 2026: Cancer map DAG, every hand-written table on the shared header filter, explained page loads explainer bodies on demand, 3,056 corpus-only cross-links
22 September 2026: GuidelineConcordance keeps the guideline body's website link: a small external-link glyph beside each stance chip in the row's cell (sibling anchor, Tab-reachable, tooltip "Open the body's website"), with the test asserting one per body cell and no nested anchors
22 September 2026: Wave 2 corpus-only joins applied: 3,056 links from fields the records already carry, links still to make down from 12,295 to 10,335 Trial to technology 2,743 links on 1,739 trials (modality technologies of the studied agents); technology to trial 211 links, 26 technologies gaining their first trial; idea to trial 133 links on 30 ideas and idea to key paper 46 links on 32 ideas, only where the idea's text names the drug or target in the idea's cancers; drug to key paper 34 links on 25 drugs; drug to trial 35 links where the title names the drug; target drugs arrays 47 links on 21 targets; company to drug 6 links on 5 companies. No EU approval rows written: 59 of the 60 snapshot candidates already had rows and the last is a withdrawn application with no date. No target-to-drug mechanism links: both measured hits were substrings.
22 September 2026: Corpus-only joins script: scripts/link-joins.ts plans and applies wave 2 links from fields the records already carry, with every rule stated; content-gaps measures corrected Ten rules, dry run by default and --apply to write through the editor in scripts/orphan-links.ts (append only, never removes a link, sorted and de-duplicated): trial to technology through the studied agents' modality technologies; idea to trial and idea to key paper only where the idea's own text names the drug or target, in the idea's cancers, for actors that trials test, capped at five and three; company to drug through sponsored trials where the drug has no maker; drug to key paper and drug to trial through titles that name the drug; technology to trial; target drugs arrays mirroring drug.targets; target to drug by whole-word mechanism mention; EU approval rows from the EMA register snapshot with the file's A, C, V and W helpers, product name and snapshot date checked.
22 September 2026: Header filters for the toolbar facets that had no column: CountryRanking gains a Region column, ScorecardTable Type and Country columns (chips that select the value) and a Regions header filter, PipelineFunnel filters the crowding table by approved product and population completeness, ResearchRanking by parent university and five-year coverage; docs/TABLES.md carries every table's state
22 September 2026: Header filters on the client tables that keep their own controls: TrialFinder, TrialFinderGeo, AssistanceBrowser, GuidelineConcordance, ManufacturingMap, InteractionChecker, AutoPulse, SurvivorshipPlan, MarketEstimator, TumorBoard, Navigator and PlanRankings filter from their column headers through useHeaderFilters and FilterHead, sharing state with the existing facet controls where one exists; CaregiverPanel skipped (eight rows, no categorical column)
22 September 2026: Trial key papers fetcher: Europe PMC by registry id, one primary and one follow-up per trial, links merged from trial-key-papers-wave1.ts
22 September 2026: Header filters on every server-rendered table: StaticTable draws plain rows from the page (links, chips, bars, avatars as small objects) so deals, evidence, funding, universities, payloads, costs, status, freshness, eval questions, survival, cited papers, papers pulse, startup investors, audit, review, China trials and deals, India sites, pathway matrix and dossier trials all filter from their column headers with a N of M count and a Clear pill; docs/TABLES.md records every table's state and the skips under ten rows
22 September 2026: Trials in plain words keeps every trial's heading, status, summary and page link in the HTML and fetches the explanation on demand: one file per cancer section, prefetched as the section scrolls near and opened with an Open explanation pill
22 September 2026: LAUNCH: owner asks of 22 Sept 2026 and what shipped in chain 96
22 September 2026: Column headers filter every browser table, tumour testing redesign with laboratory logos, Edge feed, idea and corpus rankings, explore pagination, content roadmap, PR 54 and 55 rows, signed-in bridge
22 September 2026: Cancer map: a layered DAG of every cancer type at /cancers/map/, with organ systems, histology groupings, cancers and subtypes, badges switchable between trials, products, approvals and ideas, an accessible outline, graph.json for agents, and links from the cancer browser and every family strip
22 September 2026: Rankings hub: fourteen league tables computed from corpus counts and dates, one page each with basis, coverage and a JSON companion
22 September 2026: Content roadmap: pages still to write and cross-connections still to make, measured by scripts/content-gaps.ts; waves 143 to 149 on the roadmap
22 September 2026: Edge: one feed of the freshest signals in cancer, new papers, trial results, approvals, withdrawals, law, bot proposals and weekly issues, ranked by recency with a modest importance weight, with Atom and JSON feeds at /edge/feed.xml and /edge/feed.json
22 September 2026: Tumour testing: By scope and By sample become card grids with company logos, and the table filters by sample, scope, laboratory and status from the URL query
22 September 2026: Idea rankings: six views of the same ideas at /ideas/rankings/, every score from existing fields with its formula shown
22 September 2026: Explore, For me and the navigator page their sections: the first 30 rows of each kind ship in the HTML and the rest load per section from static JSON as the reader scrolls or presses Show 30 more; For me and the navigator fetch one file per cancer instead of carrying all 328
22 September 2026: Filter from the column header: every filterable column in the results tables is a button with a funnel glyph that opens a popover of value pills (counts, search past eight, Clear, Close; bottom sheet on phones), wired to the same setter and URL as the toolbar facets; sortable headers keep sort on the label and put the filter on a sibling glyph
22 September 2026: Four EMA application withdrawals recorded as withdrawn rows, melflufen US withdrawal row restored, FDA Tazverik communication dated 11 May 2026
22 September 2026: Bridge to the signed-in site: header greets a signed-in reader, Watch keeps pages on the account with a sign-up offer, a star on every list row, For me can be saved to the account; consent copy
22 September 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
22 September 2026: Upkeep runs on its own: weekly logos, structures, trial links and acronyms, monthly identifiers, and the bots' refreshes now deploy without a manual ship
22 September 2026: Weekly maintenance and monthly identifier workflows; bot pushes now deploy through the Vercel ignore test
22 September 2026: chore: refresh literature snapshot from Europe PMC (#56)
22 September 2026: Add FDA safety communication link and SPM rate to epithelioid sarcoma record
21 September 2026: Trial phases read as plain labels everywhere: Platform trial and Observational study instead of Phase platform, with old filter links still working
21 September 2026: Phase facet test asserts the string key and the shared normaliser
21 September 2026: Facet normaliser is a string key resolved in the client, not a function crossing the server boundary
21 September 2026: Trial phases read "Observational study" and "Platform trial" instead of "Phase observational", from one phaseLabel helper
21 September 2026: A JAMA Oncology 2026 comparison of tissue-free and tumour-informed residual-disease blood tests joins the ctDNA roadmap's sources
21 September 2026: c-TRAK TN tissue-free residual-disease assay paper added and linked from the tumour-informed assay term
21 September 2026: Trial pages say what their enrolment number counts, randomised, analysed or enrolled, with the registry figure explained on hover
21 September 2026: Four new publications found by the registry check are in, including the eight-year ADAURA survival update with its figures, and the check no longer flags screening studies
21 September 2026: Registry check: a non-drug interventional study matches the corpus's observational phase, clearing the PATHFINDER 2 flag
21 September 2026: Four publications flagged by the roadmap registry check recorded as key papers: the ADAURA eight-year overall survival update (J Thorac Oncol 2026) linked from the trial and the EGFR-mutant and resectable NSCLC pages with its stage II-IIIA and IB-IIIA survival figures added to the trial's outcomes, and the FLAURA2 long-term safety analysis (Lung Cancer 2026), the KRYSTAL-12 plain language summary (Future Oncol 2026) and the TROPION-Breast01 China cohort (ESMO Open 2026) linked from their trials only; citation counts fetched from Europe PMC
21 September 2026: Trial enrolment figures now say what they count: 25 landmark trials explain why their randomised or analysed numbers differ from the registry, and five stale figures are corrected from their sources
21 September 2026: Enrolment gaps on 30 roadmap trials reviewed one by one against ClinicalTrials.gov and the primary papers: 25 keep the paper's randomised, analysed, treated or registered count and now say so in a new enrolledBasis and enrolledNote, 5 stale or unsourced figures corrected from the registry or the paper; the roadmap watch reports explained gaps separately and its offline mode re-compares against the committed registry records
21 September 2026: MIMic-01 trial status corrected to active against ClinicalTrials.gov, the first fix from the new roadmap registry check
21 September 2026: Every roadmap now carries a registry check: a weekly script compares each referenced trial with ClinicalTrials.gov and Europe PMC, flags contradictions and overdue readouts, and shows the check date under What to watch
21 September 2026: MIMic-01 status and PATHFINDER 2 design corrected against ClinicalTrials.gov, as flagged by the roadmap watch
21 September 2026: Roadmap watch for every roadmap: scripts/roadmap-watch.ts compares each roadmap's referenced trials with ClinicalTrials.gov (status, phase, enrolment within 5 percent, moved completion dates), lists Europe PMC papers since asOf, flags watch items past their expected date, writes public/roadmap-watch.json for a weekly Thursday workflow and a "Registry check" line on roadmap pages
21 September 2026: A roadmap and timeline for circulating tumour DNA tests, from the 1948 discovery of cell-free DNA to the residual-disease and multi-cancer detection trials reading out next, with a watch list and a script that checks it against the registries
21 September 2026: PATHFINDER 2 status and ECLIPSE enrolment corrected against ClinicalTrials.gov, as flagged by the ctDNA watch script
21 September 2026: ctDNA tests roadmap: ten eras from the 1948 sighting of DNA in plasma to the 2029 randomised readouts, a "What to watch" list with registry and meeting dates, six trials the corpus lacked (TRACC, MERMAID-1 and -2, BESPOKE, CIRCULATE-US, NCI Vanguard), a tumour-informed versus tumour-naive term, and npm run ctdna:watch to keep it current
21 September 2026: Twenty-six landmark papers for the pancreatic cancer pages, from PRODIGE 24 and PREOPANC to the KRAS inhibitor cohorts and the IPMN guidelines, each checked against Europe PMC
21 September 2026: Every pancreatic subtype page now rests on two to four landmark papers: 26 new records (PRODIGE 24, ESPAC-4, PREOPANC, ESPAC5, Alliance A021501, LAP07, CodeBreaK 100 and KRYSTAL-1 pancreatic cohorts, POLO and its survival analysis, the BRCA/PALB2 platinum trial, KEYNOTE-158, the NRG1 fusion discovery and zenocutuzumab papers, Fukuoka, Kyoto and European cyst guidelines, and the acinar cell carcinoma and pancreatoblastoma reference series), each DOI checked on Europe PMC and doi.org, with Le 2017 reused for the MSI-high page and citation counts fetched
21 September 2026: Seventy-four registry trials linked to the newest pancreatic and nasopharyngeal cancer pages, with a guard that keeps neuroendocrine trials off the pancreatic adenocarcinoma pages
21 September 2026: Registry trials now reach the 50 subtype pages added this week: 74 trials linked to the pancreatic disease-state and driver pages and to recurrent or metastatic nasopharyngeal carcinoma, with a neuroendocrine guard so GEP-NET trials stay off the ductal adenocarcinoma pages
21 September 2026: Pages load about three times less script: the header no longer drags in the molecule viewer, every language dictionary and the search engine, so slow connections reach a working page far sooner
21 September 2026: Bundle split follow-ups: stars JSON out of the guarded data folder, layout test reads dictionaries from the full set, row 140 done
21 September 2026: Seven European approvals corrected to withdrawn against the EMA register, the PARTIQoL proton trial gains its reported result, and the KEYNOTE-A18 papers are split into their two Lancet reports
21 September 2026: Client JavaScript on every page cut from 3.0 MB to 1.0 MB: the layout no longer pulls the animated schematics, the structure index, all eight chrome dictionaries, zod or MiniSearch
21 September 2026: Paganetti 2014 RBE reference points at the real paper (Physics in Medicine and Biology)
21 September 2026: Visit counting now asks first: Google Analytics loads only after you allow it, the browser's privacy signal is honoured, and the choice can be changed in the footer
21 September 2026: Data follow-ups: seven withdrawn EU authorisations, PARTIQoL readout, KEYNOTE-A18 split into its two Lancet papers
21 September 2026: Roadmap row 141 marked done for onco.cc
21 September 2026: Google Analytics now loads only after the visitor presses Allow: a consent bar at the foot of the viewport, the choice kept in the browser, Global Privacy Control read as No thanks, an Analytics choice control in the footer and on /privacy/, strings in nine languages
21 September 2026: GitHub star count is baked in at build time, so the top-bar badge is full from the first paint and never flickers
21 September 2026: Launch doc: two dated account notes marked as removed
21 September 2026: Launch doc: old account instructions cut to one-line history notes pointing at me.onco.cc
21 September 2026: Sign in/up opens in the same tab: links to me.onco.cc are treated as part of the site rather than external
21 September 2026: Sign in/up in the top bar now opens the WorkOS sign-in directly, with no stop on a landing page
21 September 2026: Sign in/up on onco.cc now hands you to me.onco.cc, the signed-in side; onco.cc itself keeps no account data, in the browser or the cloud
21 September 2026: Sign in/up now links to me.onco.cc; onco.cc holds no account data
21 September 2026: Sign in/up now goes straight to the WorkOS sign-in page instead of stopping at the newsletter page
21 September 2026: Greptile review config encoding the corpus rules for community pull requests
21 September 2026: Your role, cancer choice and preferences now save to your OnCo account so they follow you across devices, and the outlook block is held back pending a wording review
21 September 2026: Merge cloud profile sync; outlook block held pending wording review
21 September 2026: Community fixes: alphagenome model corrected, epithelioid sarcoma record completed with verified facts, RMC-9805 pancreatic pairing and ubamatamab mechanism corrected, plain-English outlook for ten cancers behind the survival disclosure, and 15 hidden FDA events restored
21 September 2026: Cloud profiles stage one: Supabase tables under the WorkOS token, sync, delete, privacy text
21 September 2026: PR round 2: alphagenome weights gated, FDA regulatory events surfaced, epithelioid sarcoma withdrawal history
21 September 2026: Issues 43, 45, 46, 47: prognosis outlook on ten cancer pages, ubamatamab as MUC16xCD3 bispecific with corrected citation, g12d-plus-pan-ras phase and links from the registry and company release
21 September 2026: Roadmap rows 141 and 142: GDPR compliance for accounts and HIPAA readiness
21 September 2026: chore: render this week's issue to public/newsletter/ (#52)
21 September 2026: chore: refresh public/votes.json from Discussions reactions (#51)
21 September 2026: chore: weekly fact check, audit, and provenance refresh (#50)
21 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#49)
20 September 2026: Fix duplicate entry for 'alphagenome' in model registry
18 September 2026: Health data compliance analysis: HIPAA does not apply today, GDPR and state health-data laws do; stay browser-only and prepare encrypted sync
18 September 2026: Top bar sign-in works even before the page script loads: it is now a link that upgrades to the direct WorkOS start
18 September 2026: Top bar button shortened to Sign in/up in every language, and cached pages refreshed so everyone sees the new header
18 September 2026: After sign-in a welcome page asks who you are and which cancer, the top bar shows you are signed in, four community pull requests and four issue fixes land, and secret scanning guards every commit
18 September 2026: Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics
18 September 2026: Welcome step as its own page: sign-in leaves /signup/ for /welcome/ or the return path, signed-in header pill, preferences kept with the account profile
18 September 2026: Secret scanning: gitleaks on every push and pull request, a local pre-commit hook, and an allowlist for public ids and data prose
18 September 2026: Sign up or log in button in the top bar, a medical disclaimer in the footer, and new Terms of Use and Privacy Policy pages
18 September 2026: Trastuzumab carries the June 2026 FDA approval of palbociclib with trastuzumab as HER2-positive maintenance, the one bot proposal from PR 35 not already in the corpus
18 September 2026: Pages are far lighter: the shared header, footer and cancer list are no longer copied into every page's data, and the sign-in id ships with the code
18 September 2026: Terms of use and privacy policy pages, medical disclaimer in the footer, copyright to OnCo
18 September 2026: Header: a Sign up or log in pill when signed out; region, language and search controls sit on the centre line
18 September 2026: Stop serialising the cancer list and the shared chrome into every page's payload
18 September 2026: Sign-in is live: first-time visitors choose whether they are a patient, caregiver, researcher or clinician and can set a cancer, kept only in their browser
18 September 2026: Each ship now builds once: Git-triggered Vercel builds are skipped and only the verified deploy runs
18 September 2026: First sign-in welcome step: who you are, optional cancer, browser-only profile per WorkOS user
18 September 2026: Vercel: skip Git-triggered builds so each ship builds once, from the verified CLI deploy
18 September 2026: add: Strand AI (W26) to the YC oncology list
18 September 2026: Owner list: proposal for six technology sections to lift the section kind past the size gauge
18 September 2026: Every reference DOI on the site checked against Europe PMC: four wrong links corrected, and a checker script added for future waves
18 September 2026: DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added
18 September 2026: Sixty-six landmark and classification papers for the rare-cancer pages, each checked against Europe PMC, plus two corrected reference links
18 September 2026: Two rare-cancer reference links corrected to the verified POD1UM-303 Lancet 2025 and MEK inhibition Nature 2019 papers
18 September 2026: Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR and ACT II to FIRM-ACT, PATHFINDER, HD21 and FIRSTMAPPP, linked through keyPapers
18 September 2026: Fifth Chinese quality pass over the new rare and pancreatic cancer pages: 14 corrections
18 September 2026: Four pancreatic Chinese TL;DR fixes synced from the wave export into the dictionary
18 September 2026: Chinese TL;DR pass 5: fix 14 rare and pancreatic subtype entries
18 September 2026: Eleven pancreatic cancer pages by stage and driver, from resectable and borderline disease to KRAS G12C, BRCA-mutant and MSI-high tumours, each linked from its trials and drugs
18 September 2026: Add 11 pancreatic cancer subtype pages: stage, driver and histology
18 September 2026: Thirty-nine subtype pages for rarer cancers, from anal and vulvar cancer by HPV status to Hodgkin lymphoma by stage and mastocytosis, plus an IndexNow script for changed pages
18 September 2026: Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adrenocortical, appendiceal, small bowel, cancer of unknown primary, histiocytoses, Langerhans cell histiocytosis, systemic mastocytosis, Hodgkin lymphoma, gestational trophoblastic neoplasia, pheochromocytoma and paraganglioma, nasopharyngeal and sinonasal cancers, with organ-drawing mappings, reverse links from 76 existing trial and drug records, Chinese TL;DRs registered for fold-zh and parent phrases for the cancer-families test
18 September 2026: IndexNow script: submit record pages changed since a date, batched, with a dry run
18 September 2026: Target pages with a mutation hotspot map no longer throw a hydration error: chart tooltips are written as single strings, and the page test now checks markup structure
18 September 2026: Fix hydration error 418 on target pages: multi-child SVG titles rendered empty by the server
18 September 2026: Fourth Chinese quality pass: 22 corrections across researcher, institute, trial and company summaries, including arsenic trioxide and enzalutamide names
18 September 2026: Chinese quality pass 4 over 243 folded TL;DRs
18 September 2026: Thirty-five key papers gain their DOI and PubMed ids, so every key paper but one now shows its citation count
18 September 2026: Add DOIs and PMIDs to 35 key papers that had neither
18 September 2026: Drug cards no longer nest a link inside a link, and a permanent test renders every page to forbid nested anchors site-wide
18 September 2026: Gene targets carry HGNC, Ensembl, UniProt and NCBI Gene identifiers, and key papers show how often they have been cited
18 September 2026: Guard every page against nested anchors; unnest the product card
18 September 2026: Roadmap rows 22 and 97 marked done
18 September 2026: TRACERx 2023 paper DOI corrected (ends -5, verified at doi.org)
18 September 2026: Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets
18 September 2026: Citation counts for key papers from Europe PMC (improvement 97)
18 September 2026: Dependency map hydration error fixed: vendor tiles no longer nest a link inside a link, with a test that forbids nested anchors
18 September 2026: Fix React 418 on the dependency map: no anchor inside an anchor
18 September 2026: Health pass: 369 paper links for 270 researchers, PubChem structures for 43 drugs, six glossary Wikipedia links, refreshed literature snapshots for all 2,093 tracked records, provenance for every record, and 28 logos
18 September 2026: Six more glossary terms gain Wikipedia links; 74 recorded as having no article
18 September 2026: Molecules for 43 more small-molecule and peptide drugs via PubChem name lookup
18 September 2026: Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%
18 September 2026: Trial acronym aliases completed for every registry trial that has one (115 more), so searches by study name find them all
18 September 2026: Add 115 registry trial acronyms from the CT.gov acronym field
18 September 2026: Eighty more drug companies gain Wikipedia and Wikidata links
18 September 2026: Add Wikidata ids and Wikipedia links for 80 more companies
18 September 2026: Sixty-three more institutes and 48 drug companies gain Wikipedia and Wikidata links for readers and machines alike
18 September 2026: Add Wikidata ids and Wikipedia links for 48 companies
18 September 2026: Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API
18 September 2026: Sixty-six hospitals and institutes gain Wikipedia and Wikidata links, which also feed the machine-readable sameAs data for agents
18 September 2026: Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API
18 September 2026: Final researcher identifiers pass: 64 ORCID ids and 60 Wikipedia links, taking 373 people to ORCID and 181 to Wikipedia, plus STRASS trial results
18 September 2026: Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass
18 September 2026: Seventy-seven landmark trials now show their results as structured outcomes transcribed from the published abstracts, and 146 more researchers carry ORCID ids
18 September 2026: Add structured outcomes to STRASS from its Lancet Oncology 2020 abstract
18 September 2026: Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people
18 September 2026: Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts
18 September 2026: A further 121 researchers carry ORCID ids and 18 gain Wikipedia links, each checked against their ORCID employment record
18 September 2026: Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass
18 September 2026: Subtype cancer pages now link their sibling subtypes (667 links) and 188 researchers carry ORCID ids with 22 Wikipedia links
18 September 2026: Add 188 ORCIDs and 22 Wikipedia links to people records
18 September 2026: Forty-one hospitals and institutes added and 78 researchers linked to where they work
18 September 2026: Link cancer subtypes to their siblings and name parents in tldrs
18 September 2026: Fill institutions for 78 trial investigators and add 41 institution records
18 September 2026: Five duplicate person pages merged into one each with redirects, and a duplicate finder for people added
18 September 2026: Merge five duplicate person records and add a duplicate-person finder
18 September 2026: Update weights and URLs for alphagenome model
18 September 2026: A hundred and eleven trial leads and first authors get person pages, linked from the landmark trials and key papers they led, plus 160 more trial acronyms
18 September 2026: A further 160 trial acronyms added as aliases to registry trial records
18 September 2026: Add 111 trial investigators and lead authors named by the subtype trials and key papers
18 September 2026: Trial acronyms (MARIPOSA-2, SPARTAN, CheckMate 9DX and 700 more) added as aliases to registry trial records so searches by the name patients hear find them
18 September 2026: Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases
18 September 2026: Seventeen more landmark trials named on subtype pages (ATTRACTION-2, MAIA, RESONATE-2, NeoSphere and others) recorded with confirmed registry ids, and acronyms added to three registry records
18 September 2026: Third Chinese quality pass: 19 corrections to new drug, company and trial summaries, including wrong drug names and Korean text left in Chinese sentences
18 September 2026: Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled
18 September 2026: Third Chinese quality pass: 19 of 236 TL;DRs from the biomarker, drug, maker and trial waves corrected, and the 73 trial TL;DRs folded into zh.ts
18 September 2026: Seventy-three trials named on subtype pages now have their own records with confirmed registry ids, plus logos for the new drug makers
18 September 2026: Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)
17 September 2026: Seventy-four drug makers added and 210 drug-to-company links filled, so pipeline drugs now show who is developing them
17 September 2026: Link 193 company-less drugs to their makers and add 74 maker records
17 September 2026: Key papers for 147 subtype pages: 364 pivotal trial, classification and guideline papers, each checked against Europe PMC
17 September 2026: Add key papers to 147 cancer subtype pages
17 September 2026: Thirty-nine drugs named by the new subtype pages now have their own records, from hormone therapies for pituitary tumours to antibody-drug conjugates in trials
17 September 2026: Add drugs named by the cancer subtype pages (drugs-subtypes-wave)
17 September 2026: Fifty biomarker glossary terms named by the new subtype pages (molecular groups, risk scores, resistance mutations), each linked from the pages that use it
17 September 2026: Add 50 biomarker terms named by the cancer subtype pages
17 September 2026: Registry trials linked to 109 subtype pages by driver and stage (1,018 links), with a re-runnable matcher script
17 September 2026: Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens
17 September 2026: Plain-English sentences for the 170 new subtype pages and trials, so every record carries one again
17 September 2026: Add simple sentences for the subtype-wave cancer pages and trials (part-s)
17 September 2026: Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;DRs from tonight's new pages, including one inverted meaning, and adopts NMPA drug names
17 September 2026: Review Chinese TL;DRs of the subtype waves: standard drug names, terms and alignment with the English
17 September 2026: Merge duplicate trial records onto their named keepers
17 September 2026: Head and neck cancers by HPV status and site: HPV-positive and HPV-negative disease, recurrent or metastatic squamous cell carcinoma, hypopharyngeal cancer, three salivary gland histologies and three oral cavity subsites, tied to KEYNOTE-048, RTOG 1016, De-ESCALaTE, ECOG 3311, PATHOS and NIVOPOSTOP
17 September 2026: Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic state page, hypopharyngeal, adenoid cystic, salivary duct, mucoepidermoid, oral tongue, gingivobuccal (India) and lip, with NIVOPOSTOP, ECOG-ACRIN E3311, PATHOS and CAPTAIN-1st
17 September 2026: Neuroendocrine neoplasms by site and grade: small intestinal, pancreatic and lung neuroendocrine tumours, grade 3 NET and extrapulmonary neuroendocrine carcinoma, tied to NETTER-1 and 2, CLARINET, PROMID, RADIANT and CABINET; NETTER-2 refiled under neuroendocrine cancer
17 September 2026: Add neuroendocrine subtypes by site and grade
17 September 2026: Childhood cancers by type and risk: acute lymphoblastic leukaemia by risk group, Philadelphia status, infancy and relapse, paediatric AML, neuroblastoma by risk group, medulloblastoma by molecular group, and a page for adolescents and young adults
17 September 2026: Add paediatric cancers by type and risk group
17 September 2026: Sarcomas and bone tumours by type: chondrosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, alveolar soft part sarcoma, PEComa, epithelioid haemangioendothelioma, nerve sheath tumours, retroperitoneal and extremity soft tissue sarcoma, with STRASS, EORTC 62012, AMPECT and ANGIOTAX
17 September 2026: Add sarcoma and bone tumour subtype pages with landmark trials
17 September 2026: Cancer pages by state for the common cancers: gynaecological cancers by molecular class and stage, skin cancers by state, lung cancer by driver and stage, breast cancer by state, 44 pages tied to their landmark trials and drugs; the My cancer chip leaves the header until accounts are on
17 September 2026: Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive brain metastases, early and metastatic triple-negative, inflammatory breast cancer, Paget disease of the nipple and phyllodes tumour, each linked from the trials and drugs that treat them
17 September 2026: Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials
17 September 2026: Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP
17 September 2026: Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or recurrent endometrial cancer, uterine carcinosarcoma, cervical cancer by stage (early and fertility-sparing, locally advanced, recurrent or metastatic) and ovarian cancer by platinum sensitivity, each tied to its landmark trials and drugs
17 September 2026: Blood cancers by state: acute myeloid leukaemia by driver and fitness, acute promyelocytic leukaemia, myeloma from smouldering to relapsed, MDS by risk, CLL by line and Richter transformation, CML by phase and primary myelofibrosis, nineteen pages tied to 111 drugs and trials
17 September 2026: Blood cancers by driver, state and phase: nineteen subtype pages
17 September 2026: Upper gastrointestinal and liver cancers by state: gastric cancer by HER2, CLDN18.2, PD-L1 and MSI status and early gastric cancer, hepatocellular carcinoma by BCLC stage, intrahepatic and extrahepatic cholangiocarcinoma, and GIST by mutation, each tied to its landmark trials and drugs
17 September 2026: Colorectal cancer by state: rectal, MSI-high, BRAF V600E, HER2-amplified, KRAS G12C and early-onset pages with OPRA, PROSPECT, BEACON and other landmark trials; primary mediastinal B-cell lymphoma
17 September 2026: Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIST by mutation
17 September 2026: Brain tumour subtypes: IDH-mutant astrocytoma, oligodendroglioma, meningioma, brain metastases, paediatric high-grade glioma, spinal cord tumours, vestibular schwannoma and CNS germ cell tumours, each linked from the drugs and trials that treat them
17 September 2026: Add colorectal subtype pages and primary mediastinal B-cell lymphoma
17 September 2026: Add brain and spinal tumour subtype pages
17 September 2026: Plain-English sentences for every remaining record: 1,167 early-phase trials, 138 people, 65 companies, 8 institutions and 3 ideas, so all 11,306 records now carry one
17 September 2026: Simple layer: part-r, fourth and final wave to full coverage
17 September 2026: Websites for 15 organisations and nine more logos, with archived addresses replaced by live sites; roadmap row 139 records the open dependency map hydration mismatch
17 September 2026: Add official websites to 15 sponsor records and fetch nine logos
17 September 2026: Roadmap row 139: dependency map hydration mismatch
17 September 2026: 969 more plain-English sentences for early-phase trials, key papers and collections, taking the simple layer to 9,930 records; one non-cancer registry record removed
17 September 2026: Simple layer wave 3: part-q with 969 sentences (trials, papers, collections)
17 September 2026: Orphan trials given content: ten drug matches, 17 sponsor aliases, 36 sponsor companies and 130 trials tied to their makers, two non-cancer records removed; backlinks round: 303 weakly linked records gain true relations from their own text; orphans down to 214
17 September 2026: After the trial removals: no dangling references, floor re-run, sponsor wave three Chinese folded
17 September 2026: Backlink fill: text-supported relations for 303 weakly connected records
17 September 2026: 1,024 more plain-English sentences: 279 companies, 104 institutions and 640 phase 3 trials, taking the simple layer to 8,961 records
17 September 2026: Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (wave 3); remove two myasthenia gravis records
17 September 2026: Papers for 36 more researchers matched by institution; trial snapshots refreshed for all 1,024 products with 136 registry changes detected; paper snapshots refreshed for all 1,924 records
17 September 2026: Add simple part-p: 1024 plain sentences for companies, institutions, the theories pathway and phase 3 trials
17 September 2026: One papers block per person after the two paper waves met
17 September 2026: People papers: 36 more research-trained people via OpenAlex and Europe PMC
17 September 2026: docs(corrections): name the reporting clinician on the two glioblastoma rows
17 September 2026: Company content and sources for 33 makers, 26 sponsor corrections and papers for twelve researchers; 7,065 reverse links take orphaned trials from 2,467 to 279; Wikipedia links for six terms; structured outcomes with sources for 26 trials; 153 new logos; the schematic gauge counts aliased drawings
17 September 2026: Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge
17 September 2026: Schematic gauge counts aliased drawings as specific
17 September 2026: Add Wikipedia links to six terms lacking one
17 September 2026: Fold a doubled relation line after the sponsor merge
17 September 2026: Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them back; orphan floor 2572 to 384
17 September 2026: Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people
17 September 2026: 661 plain-English sentences: every cancer, 201 drugs, 179 technologies, 120 terms, 50 phase 3 trials and 63 targets; 451 reverse links give 126 orphaned drugs and 105 companies their first inbound link, with three maker corrections
17 September 2026: Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list them back; orphan floor 2827 to 2572
17 September 2026: Simple layer: part-o with 661 sentences, layer test
17 September 2026: Machine translation pipeline for record summaries with hash-checked cache and a report link; 157 Chinese summaries live (every cancer page and nine glossary terms) and two Spanish; model review panel populated for twenty cancers by Fable, each verdict tied to the record's own sources
17 September 2026: Every record has its own RDF Turtle file at /api/v1/rdf/<id>.ttl, linked from the page head, the hidden machine links, JSON-LD, the OpenAPI document and llms.txt
17 September 2026: Machine-translated summaries: cached per record and language under public/i18n/summaries, shown only while the English hash matches, marked as machine translated with a report link and an English toggle; prioritised batch script with a fetch call to the Messages API and a validator for NCT ids, doses, gene symbols and leftover English; hand-written Spanish and Chinese examples for pCR; coverage script counts them
17 September 2026: Per-record RDF: one Turtle file per record at /api/v1/rdf/<id>.ttl, linked from every record page
17 September 2026: For me from a real situation: setting, biomarkers, treatments had, country and trial interest drive what is standard, what your biomarkers change, trials that fit, warnings and questions, all from record fields with sources; dependency map renders identically on server and client
17 September 2026: Theme stays light even when React recovers from a hydration mismatch; the counts grid fills its rows again with twenty kinds
17 September 2026: Fix hydration mismatch on the dependency map
17 September 2026: For me from a real situation (roadmap item 101): setting, biomarkers, treatments had, country and trials drive record-backed sections
17 September 2026: Machines of oncology, second wave: 23 more machine families from boron neutron capture and FLASH beams to hyperthermia, fluorescence surgery, positioning, gating and dosimetry, with 32 vendors; roadmap rows marked done for the day's work
17 September 2026: Decisions you may face: a page per cancer laying out each treatment setting's options, evidence and trade-offs; expert centres as a sortable table of what can be measured, with a near-you marker; your remembered cancer follows you through the header, home, hubs, trials and search; a what-changed page per cancer; red cards for warnings on cancer pages
17 September 2026: Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, endoscopy, skin and cervical imaging, RT guidance and QA, CSTDs
17 September 2026: Prostate cancer by state: eight subtype pages from low risk to neuroendocrine, linked from 45 trials and drugs; Tregzi added from the FDA notice and the remaining update bot proposals checked against the registry; Hansoh merged into one record with a redirect
17 September 2026: Patient roadmap 102, 104, 106: remembered cancer, per-cancer what changed, red cards
17 September 2026: Decision pages per cancer and outcome-based centre tables (roadmap items 107 and 108)
17 September 2026: Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge
17 September 2026: Chinese quality pass: 82 TL;DRs corrected (standard NMPA drug names, basket trial term, methotrexate spelling, idioms), account strings in the formal register
17 September 2026: Radiation wave 5: LET, RBE and when protons beat IMRT
17 September 2026: Chinese quality pass on today's TL;DRs and interface strings: 篮式试验 for basket trial, 甲氨蝶呤 typo, 磁共振直线加速器, established drug names in 61 templated trial lines, natural wording in 30 machine-flavoured sentences, 您 throughout the account strings
17 September 2026: First sixty days after diagnosis: a week-by-week guide for every cancer built from its records, and a printable appointment sheet per cancer with questions, words you may hear and treatments you may be offered
17 September 2026: Model review panel: schema, batch script and page for AI model commentary on records, with two example panels; diagnostics wave two: 24 tests from RAD51 foci and CTC counts to pharmacogenomics, cardiac markers and low-resource screening, with five companies; institution networks: Parker Institute members and leaders, CRUK, NCI, UNICANCER and DKTK links, and ten weakly linked centres strengthened
17 September 2026: Add the first 60 days guide and per-cancer appointment sheets
17 September 2026: Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institution pages
17 September 2026: Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)
17 September 2026: Animations pause off screen, when the tab is hidden and on slow phones, with a shared budget of six spinning molecules or drawings at once; the record page sidebar stays inside its column and never reaches the footer
17 September 2026: Model panel: AI models comment on records beside the human review path
17 September 2026: Search results page as an index: kind chips, did-you-mean, pages strip, Ask OnCo card, related strip; 29 trial design terms and a design picker page; startup requests ranked by urgency and commerciality with every input cited; 51 law and regulation terms by jurisdiction with a law page; translation hygiene: language tags, no-translate on names and doses, a browser translation offer
17 September 2026: Animation budget for slower phones: one hook (use-animation-budget) pauses molecules, wireframe schematics, the docking scene, the garden sway, the body map, the resistance map and the steppers when off screen or the tab is hidden, draws a still frame under reduced motion, caps thumbnails at six spinning per kind, animates on tap on Save-Data or four-core devices, defers structure fetches until on screen, lazy-loads the gallery 3D viewer; record page sidebar confined to its grid column and not sticky when taller than the viewport; roadmap rows 127 and 138
17 September 2026: Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)
17 September 2026: Manufacturing in oncology: seven supply chains, 18 technologies and 14 makers; theories of cancer: a hub map and sixteen theory records with status; platform trials at depth: 21 master protocol trials and a hub term; technology dependency map with 119 edges and a viewer; Chinese TL;DRs folded in for every new record
17 September 2026: Browser translation and language attributes (roadmap row 128, part three): summaries, field values, data tables, bullets and table bodies carry lang="en" while TL;DRs keep their own language; drug, gene, company, trial and person names, aka lines, NCT ids, gene symbols, database ids, molecule labels, formulas and doses carry translate="no" with the notranslate class; TranslateOffer shows one dismissible line at the top of the main column that switches to a carried language or explains the browser's translator in nine languages; wireframe canvas labels repeated as hidden real text; scripts/translation-coverage.ts measures the share of a page in the chosen language per kind
17 September 2026: Rank startup requests by urgency and commerciality (row 112)
17 September 2026: Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)
17 September 2026: Search results page as a proper index (roadmap row 123)
17 September 2026: Manufacturing wave: remove the Hitachi remnant
17 September 2026: Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella trials, STAMPEDE enriched
17 September 2026: Theories of cancer: hub map and sixteen theory records in the mechanics section
17 September 2026: One Hitachi record (machines wave)
17 September 2026: Machines of oncology: 21 machine technologies, 17 vendors and 66 centres with their proton, carbon, MR-linac, Gamma Knife and other rare machines, with a machines page; Free in oncology page with 62 services; tumour sequencing tests compared across 13 laboratories; useful 404 page with nearest matches; section tabs, aligned header icons and unsqueezed tables; machine-readable links, Wikidata sameAs and short titles for search engines and agents; footer credit; navigation starts at the top
17 September 2026: Technology dependency DAG viewer (roadmap 134)
17 September 2026: Manufacturing wave: seven supply chains, 18 technologies, 14 makers
17 September 2026: Merge fixes: single Strata Oncology record, Chinese dictionary without duplicate keys
17 September 2026: Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres
17 September 2026: Free in oncology and tumour sequencing test pages (roadmap 117, 118)
17 September 2026: SEO and agent surface on record pages: titles within 60 chars, Wikidata sameAs, hidden machine-readable landmark
17 September 2026: Compact section tabs, table column widths and header icon alignment
17 September 2026: Make the 404 page useful: nearest matches, ways in, local miss log
17 September 2026: Tables: one shared stand-in for rows with no picture, so no visual slot is ever an empty gap
17 September 2026: Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall through to the profile link; drawer close button without a border; pills never break inside a word; page titles capitalised; landing cards show a corner arrow; off-site links open in a new tab; intoDNA STRIDE and Strata Oncology with sequencing links for testing companies; roadmap rows 115 to 121
17 September 2026: Accounts through WorkOS: browser-only sign-in behind the same account functions, recorded in WorkOS, on when the client id is set; README retitled Total information dominance on cancer with an open-repository note and a screenshot gallery; site title to match; pivot modality headers use one classifier so every header links
17 September 2026: Search index is fresh on every visit (service worker network-first for the API, cache rule narrowed to snapshots and images); site pages ranked higher in search; models table shows each maker's logo or an initials tile; orphan detector script and ratchet test; hub page linked from digital twins
17 September 2026: Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancreatic cancer wave: four failed phase 3 programmes, nimotuzumab's NOTABLE approval, elraglusib, their sponsors and cross-links; PDAC and Cloudflare rows on the roadmap
17 September 2026: Merge PRs 25, 28 and 29 (CheckMate split, topic cards, WebMCP); mobile region menu stays on screen; one heading per cancer group; bevacizumab NICE note; glioblastoma MGMT and tovorafenib wording; mathematical models hub and site pages in search; long lists load in pages as you scroll
17 September 2026: Add progressive WebMCP tools for public oncology search and lookup
17 September 2026: fix: filter cancer topic cards by relevance
17 September 2026: fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6
17 September 2026: Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-long cache headers for snapshots; Cloudflare caching on the roadmap
17 September 2026: Changelog sync keeps the pending entry through the build
17 September 2026: Changelog kept current from the commit log; linked from the README
17 September 2026: Link 51 new technologies back from their drugs, targets and base drawings
17 September 2026: Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers
17 September 2026: Link 28 cancer subtype pages from the drugs and trials that treat them
17 September 2026: Refresh provenance for this week's records
17 September 2026: Cancer links for 20 unlinked trials; Chinese version complete for trials
17 September 2026: Watch button confirms each click
17 September 2026: Country pages: cancer site labels link to their OnCo pages in both tables
17 September 2026: Chinese TL;DRs for the last 87 curated trials and drugs
17 September 2026: Mathematical and biophysical models: 22 model technologies, a third type on the models page
17 September 2026: Types strip as pills, navigator visuals, account-style signup, linked grid headers
17 September 2026: chore: refresh pulse, abstract and citation snapshots (#20)
17 September 2026: chore: refresh institution research output from OpenAlex (#17)
17 September 2026: chore: draft change proposals from feed snapshots
16 September 2026: Add Anocca; biophysics sources as data-source candidates
16 September 2026: Prevalence rows for 20 more targets
16 September 2026: Prevalence rows for 36 targets
16 September 2026: Molecules for 26 more drugs and tracers
16 September 2026: Molecules for 29 more small-molecule drugs
16 September 2026: Pipelines and missing rows for 29 new cancer pages
16 September 2026: Keep the corpus out of the tool pages' JavaScript
16 September 2026: Keep the corpus out of the guideline pages' JavaScript
16 September 2026: Load translation tables on demand; Chinese TL;DRs for 2,678 registry records
16 September 2026: Chinese TL;DRs for the remaining 131 people
16 September 2026: Subtype pages: leiomyosarcoma, liposarcoma, synovial sarcoma, marginal zone lymphoma, cutaneous T-cell lymphoma
16 September 2026: Subtype pages: kidney, testicular, oesophageal, bladder
16 September 2026: Fix accessibility regressions in shared UI components
16 September 2026: Subtype pages: thyroid, head and neck, ovarian
16 September 2026: Chinese TL;DRs for every company, institution, term and idea
16 September 2026: Radiation wave 4 (21 landmark trials) and Chinese TL;DRs for every cancer, target, technology and curated drug
16 September 2026: Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs
16 September 2026: check-links: separate blocked from broken in the report (#15)
16 September 2026: Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112
16 September 2026: Mobile search opens into the box; radiation wave 1
16 September 2026: Add SciRouter, a prevention-first longevity start-up
16 September 2026: Molecules for 31 small-molecule drugs; gumarontinib folded into glumetinib
16 September 2026: Essential thrombocythaemia page, aspirin record, vorolanib
16 September 2026: Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas
16 September 2026: China deep dive: fifteen trial sponsors as company records
16 September 2026: Offline page only on real failures, China wave 1, favicon set
16 September 2026: Registry trials wave 6 and products wave 7
16 September 2026: Clickable breadcrumbs, pipeline products wave 6, checklist additions
16 September 2026: Header signup, trial wave 5 and Ask weighting
16 September 2026: trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recorded drug and cancer (295 to their sponsor); wave 3 trials gain sponsor links; search lifts the kind named at the start of a question so a 'drug for' query ranks drugs above trials and people
16 September 2026: data: pipeline wave 2 from ClinicalTrials.gov, curated: 27 products missing from the corpus (ten China-approved kinase and checkpoint drugs, Japan's amrubicin and pirarubicin, tabelecleucel, HER2 and GDF-15 antibodies, PSMA and CAIX PET tracers, CD45 radioimmunotherapy and others) with 32 phase 3 trial records and China regional rows; launch checklist gains the agentic and AI accessibility to-do
16 September 2026: cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer, NUT carcinoma) with state of the art, history and development pipelines; six trials (TIGER, SABR-COMET, the tazemetostat run-in, three NUT carcinoma trials) and the BET inhibitor ZEN-3694; gaps page counts only developers as missing products
16 September 2026: site: Google Analytics tag with an honest disclosure on the about page; refresh workflows merge their own pull requests once validate and tests pass (the proposals workflow stays a human gate); deploys the FCCT directory and the nine merged weekly snapshots
16 September 2026: chore: draft change proposals from feed snapshots (#1)
16 September 2026: chore: refresh pulse, abstract and citation snapshots (#2)
16 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#3)
16 September 2026: chore: refresh public/votes.json from Discussions reactions (#5)
16 September 2026: chore: weekly citation link check (#7)
16 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#8)
16 September 2026: chore: refresh preprint tracker from Europe PMC (#9)
16 September 2026: chore: check regional approvals against the EMA register (#10)
16 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#11)
16 September 2026: data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and the FCCT directory brought in: 39 suppliers, tools and services and 10 clinics and centres for tissue preservation, tumour profiling, functional drug testing, liquid biopsy, theranostics, vaccines, cell therapy, trial finding and navigation
16 September 2026: owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton therapy trial and an idea on why ADCs have failed in mesothelioma; cancer pages replace the curated Pipeline list with an In development tab built from the whole corpus; Even One Ventures and fourteen portfolio companies with a weekly-refreshed universe list
16 September 2026: data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indication (historic hormonal and cytotoxic agents, photodynamic and diagnostic agents, growth factors, antiemetics, drugs approved in Japan, China, India or Australia); approval pill no longer wraps
16 September 2026: header: profile icon on every page opens an email capture dialog (magic-link sign-in when accounts are on, list endpoint otherwise); weekly-issue signup boxes removed from footer and newsletter page; strings in nine languages

Upcoming readouts and decisions, next 30 days

Decisions, advisory committees, expected readouts and congresses from the readout calendar. Expected dates are editorial estimates.

2026-10-23 · ESMO Congress 2026, Madrid (23 to 27 October) (confirmed) · European Society for Medical Oncology (ESMO) · source

Corrections, past 7 days

Confirmed factual corrections to the corpus, with the fixing commit.

2026-10-01 · Lirafugratinib: Recorded as "an experimental small-molecule drug from Elevar Therapeutics in phase 2 trials". The FDA approved it on 23 September 2026 for previously treated cholangiocarcinoma with an FGFR2 fusion or other rearrangement. The record also named no cancer. (The weekly FDA feed, proposed by the update bot and checked against the FDA notice.) · Status, brand, summary, the cancer, the approval row and the regional row all corrected from the FDA notice. The bot's proposed note omitted the FGFR2 restriction; the restriction is in the row.
2026-10-01 · The update bot's FDA matcher: A product whose name is a combination matched any notice naming one of its partners, so "accelerated approval to vusolimogene oderparepvec with nivolumab for melanoma" was proposed as a regulatory event on Relatlimab + nivolumab. Proposed twice, on 30 September and 1 October, and caught by hand both times. (Reviewing the proposals queue.) · A combination is matched only when every component is named. scripts/propose-updates.test.ts holds the rule.
2026-09-30 · Red cards on every antibody-drug conjugate (brentuximab vedotin): The class card matched every product whose modality is "ADC", so a reader on brentuximab vedotin was told to watch for the Stevens-Johnson reaction that enfortumab vedotin carries, and a reader on an investigational ADC with no warnings got the same card. (Writing the lymphoma standard-of-care rows and reading the rendered page.) · The named warnings attach by product id; the class set keeps only the neutropenic fever card. src/lib/red-flags.test.ts fails against the old code.
2026-09-30 · Differentiation syndrome on bexarotene: The set matched the fragment "retinoid", so bexarotene, an RXR agonist given for cutaneous T-cell lymphoma, carried a warning that belongs to ATRA and arsenic trioxide in acute promyelocytic leukaemia. Bexarotene's label carries no such warning. (Same read.) · The set now matches the modality phrase "differentiation agent".
2026-09-30 · NICE TA892, mosunetuzumab: Recorded as available through the Cancer Drugs Fund. Recommendation 1.1 reads "is not recommended". (Reading every lymphoma appraisal on nice.org.uk.) · Changed to not recommended.
2026-09-30 · NICE TA524: Described as the cutaneous T-cell lymphoma appraisal. TA524 is the Cancer Drugs Fund review carrying the Hodgkin lymphoma recommendation; the CTCL appraisal is TA577. (Same sweep.) · Corrected to TA577.
2026-09-30 · NICE TA649, polatuzumab vedotin: Recorded as Cancer Drugs Fund; recommendation 1.1 is routine commissioning. TA933 was recorded as "not recommended" when it is a terminated appraisal. (Same sweep.) · Both corrected.
2026-09-30 · Fentanyl and resminostat structures: The weekly maintenance run added PubChem CID rows for two compounds that already had name-lookup rows, and the duplicate key would not compile. (Typecheck after merging the weekly maintenance branch.) · The name-lookup rows removed; the explicit CID kept, because it cannot drift when PubChem renames a synonym.
2026-09-25 · Red flags, urgent advice (symptoms): The UKONS source constant in src/data/red-flags.ts pointed at ukons.org/site/assets/files/1134/oncology_haematology_24_hour_triage.pdf, which 404s with an HTML page after a site move. Nine urgent-advice rows cited it. (Source sweep of every URL in src/data/red-flags.ts, checked on content type and size rather than status) · Repointed at the current UKONS Oncology/Haemato-oncology 24-hour triage toolkit version 3 (application/pdf, 652,152 bytes), linked from ukons.org resources
2026-09-25 · Red flags, urgent advice (symptoms): Six thresholds attributed to the UKONS triage tool were not in it. "Signs of sepsis" listed cold or mottled skin and very low urine output; "Breathlessness" said blue lips; "Uncontrolled vomiting or diarrhoea" said unable to keep fluids down for 24 hours and seven or more stools a day; "Bleeding" said 15 minutes of pressure, blood in vomit, urine or stool and a sudden severe headache; "Confusion or drowsiness" said difficulty speaking and a seizure; "Rash that blisters" said sores in the mouth, eyes or genitals. (Each row read against the toolkit's own grading table after the URL was repaired) · Rows reworded to the toolkit's wording (breathlessness at rest or any chest pain; 6 or more vomits in 24 hours; an increase of 7 or more bowel movements a day over pre-treatment normal; bleeding that is not self-limiting; severe confusion or an altered level of consciousness; a rash over 30 percent of the body with blistering or ulceration). The sepsis row now cites the NHS sepsis page, which states those 999 signs
2026-09-25 · Red flags, urgent advice (symptoms): Five more source URLs silently redirected: NHS blood clots, diarrhoea and vomiting, vomiting blood, and three Pancreatic Cancer UK pages under /information/. (Same sweep) · Updated to the pages the redirects land on
2026-09-25 · 62 FDA label citations (accessdata.fda.gov): The weekly link check recorded every accessdata.fda.gov label as gone: the site redirects non-browser clients to /apology_objects/abuse-detection-apology.html and serves it with a 404. The documents are live. (A new test comparing red-flag sources against public/links.json) · scripts/check-links.ts now classifies a bot-wall interstitial as blocked rather than gone